U.S. Stem Cell (USRM) 10-K 25 Mar 14 2013 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013	Mar. 24, 2014	Jun. 30, 2013
Document and Entity Information [Abstract]	'	'	'
Entity Registrant Name	'BIOHEART, INC.	'	'
Entity Central Index Key	'0001388319	'	'
Document Type	'10-K	'	'
Document Period End Date	31-Dec-13	'	'
Amendment Flag	'false	'	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Well-Known Seasoned Issuer	'No	'	'
Entity Voluntary Filers	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Filer Category	'Smaller Reporting Company	'	'
Entity Public Float	'	'	$4,061,603
Entity Common Stock, Shares Outstanding	'	420,920,157	'

Balance_Sheets

Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012
Current assets:	'	'
Cash and cash equivalents	$46,227	'
Accounts receivable, net	19,913	1,342
Inventory	'	62,953
Prepaid and other	784	41,533
Total current assets	66,924	105,828
Property and equipment, net	9,055	1,820
Other assets	10,160	54,662
Total assets	86,139	162,310
Current liabilities:	'	'
Bank overdraft	'	89
Accounts payable	2,382,267	2,556,043
Accrued expenses	4,480,335	4,731,488
Advances, related party	416,198	313,448
Deposits	478,286	465,286
Subordinated debt, related party	1,500,000	1,500,000
Notes payable, related party	2,241,477	2,215,324
Notes payable, net of debt discount	1,930,841	2,364,972
Total current liabilities	13,429,404	14,146,650
Derivative liability	403,811	611,227
Stockholders' deficit:	'	'
Preferred stock, par value $0.001; 20,000,000 and 5,000,000 shares authorized as of December 31, 2013 and 2012, respectively, 20,000,000 and 0 issued and outstanding as of December 31, 2013 and 2012, respectively	20,000	'
Common stock, par value $0.001; 950,000,000 and 195,000,000 shares authorized as of December 31, 2013 and 2012, respectively, 379,787,745 and 182,062,802 shares issued and outstanding as of December 31, 2013 and 2012, respectively	379,788	182,063
Additional paid in capital	103,819,119	100,260,094
Common stock subscription	215,000	'
Deficit accumulated during development stage	-118,180,983	-115,037,724
Total stockholders' deficit	-13,747,076	-14,595,567
Total liabilities and stockholders' deficit	$86,139	$162,310

Balance_Sheets_Parenthetical

Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Balance Sheet [Abstract]	'	'
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	20,000,000	5,000,000
Preferred stock, shares issued	20,000,000	0
Preferred stock, shares outstanding	20,000,000	0
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	950,000,000	195,000,000
Common stock, shares issued	379,787,745	182,062,802
Common stock, shares outstanding	379,787,745	182,062,802

Statements_of_Operations

Statements of Operations (USD $)	12 Months Ended		173 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Statements Of Operations [Abstract]	'	'	'
Revenue	$96,085	$61,109	$1,365,725
Cost of sales	30,831	1,070	582,735
Gross profit	65,254	60,039	782,990
Operating expenses:	'	'	'
Research and development	626,983	401,941	65,320,035
Marketing, general and administrative	2,267,831	2,178,352	39,105,667
Impairment of investment	'	'	58,695
Depreciation and amortization	2,190	14,589	900,104
Total operating expenses	2,897,004	2,594,882	105,384,501
Net loss from operations	-2,831,750	-2,534,843	-104,601,511
Other income (expenses):	'	'	'
Development revenues	'	'	117,500
Gain on extinguishment of debt	1,023,439	'	1,023,439
Gain on change of fair value of derivative liability	29,179	119,795	123,948
Interest income	'	'	762,277
Other income	73,756	18,234	344,821
Interest expense	-1,437,883	-1,619,653	-15,951,457
Total other income (expenses)	-311,509	-1,481,624	-13,579,472
Net loss before income taxes	-3,143,259	-4,016,467	-118,180,983
Income taxes (benefit)	'	'	'
NET LOSS	($3,143,259)	($4,016,467)	($118,180,983)
Net loss per common share, basic and diluted	($0.01)	($0.03)	'
Weighted average number of common shares outstanding, basic and diluted	251,828,970	146,463,828	'

Statement_of_Stockholders_Defi

Statement of Stockholders Deficit (USD $)	Total	Preferred stock	Common stock	Additional Paid in Capital	Deferred Compensation	Subscription Receivable	Deficit Accumulated During Development Stage
Beginning Balance at Aug. 12, 1999	'	'	'	'	'	'	'
Beginning Balance, Shares at Aug. 12, 1999	'	'	'	'	'	'	'
Issuance of common stock	400,000	'	4,324	395,676	'	'	'
Issuance of common stock, Shares	4,324,458	'	4,324,458	'	'	'	'
Stock based compensation	'	'	'	98,000	-98,000	'	'
Amortization of stock based compensation	49,000	'	'	'	49,000	'	'
Net loss	-903,290	'	'	'	'	'	-903,290
Balance at Dec. 31, 1999	-454,290	'	4,324	493,676	-49,000	'	-903,290
Balance, Shares at Dec. 31, 1999	'	'	4,324,458	'	'	'	'
Issuance of common stock	9,608,695	'	1,494	9,607,201	'	'	'
Issuance of common stock, Shares	1,493,575	'	1,493,575	'	'	'	'
Stock based compensation	'	'	'	2,559,000	-2,559,000	'	'
Amortization of stock based compensation	1,080,692	'	'	'	1,080,692	'	'
Fair value of warrants issued in exchange for licenses and intellectual property	5,220,000	'	'	5,220,000	'	'	'
Contributed capital	1,050,000	'	'	1,050,000	'	'	'
Common stock issued in exchange for services	52,001	'	8	51,993	'	'	'
Common stock issued in exchange for services, shares	7,964	'	7,964	'	'	'	'
Net loss	-14,113,933	'	'	'	'	'	-14,113,933
Balance at Dec. 31, 2000	2,443,165	'	5,826	18,981,870	-1,527,308	'	-15,017,223
Balance, Shares at Dec. 31, 2000	'	'	5,825,997	'	'	'	'
Issuance of common stock	6,283,004	'	986	6,282,018	'	'	'
Issuance of common stock, Shares	985,668	'	985,667	'	'	'	'
Stock based compensation	'	'	'	779,000	-779,000	'	'
Amortization of stock based compensation	1,523,000	'	'	'	1,523,000	'	'
Common stock issued in exchange for services	54,001	'	8	53,993	'	'	'
Common stock issued in exchange for services, shares	8,291	'	8,291	'	'	'	'
Conversion of contributed capital to common stock	'	'	81	-81	'	'	'
Conversion of contributed capital to common stock, shares	81,084	'	81,084	'	'	'	'
Net loss	-8,173,464	'	'	'	'	'	-8,173,464
Balance at Dec. 31, 2001	2,129,706	'	6,901	26,096,800	-783,308	'	-23,190,687
Balance, Shares at Dec. 31, 2001	'	'	6,901,039	'	'	'	'
Issuance of common stock	7,076,198	'	1,093	7,075,105	'	'	'
Issuance of common stock, Shares	1,092,883	'	1,092,883	'	'	'	'
Stock based compensation	'	'	'	143,521	-143,521	'	'
Amortization of stock based compensation	613,083	'	'	'	613,083	'	'
Common stock issued in exchange for services	227,503	'	35	227,468	'	'	'
Common stock issued in exchange for services, shares	35,137	'	35,137	'	'	'	'
Net loss	-9,257,954	'	'	'	'	'	-9,257,954
Balance at Dec. 31, 2002	788,536	'	8,029	33,542,894	-313,746	'	-32,448,641
Balance, Shares at Dec. 31, 2002	'	'	8,029,059	'	'	'	'
Issuance of common stock	3,182,274	'	562	3,181,712	'	'	'
Issuance of common stock, Shares	561,701	'	561,701	'	'	'	'
Stock based compensation	'	'	'	-155,893	155,893	'	'
Amortization of stock based compensation	79,371	'	'	'	79,371	'	'
Common stock issued in exchange for services	823,887	'	144	823,743	'	'	'
Common stock issued in exchange for services, shares	'	'	144,300	'	'	'	'
Net loss	-6,037,528	'	'	'	'	'	-6,037,528
Balance at Dec. 31, 2003	-1,163,460	'	8,735	37,392,456	-78,482	'	-38,486,169
Balance, Shares at Dec. 31, 2003	'	'	8,735,060	'	'	'	'
Issuance of common stock	4,580,913	'	809	4,580,104	'	'	'
Issuance of common stock, Shares	808,570	'	808,570	'	'	'	'
Stock based compensation	'	'	'	637,858	-637,858	'	'
Amortization of stock based compensation	148,812	'	'	'	148,812	'	'
Common stock issued in exchange for services	96,331	'	17	96,314	'	'	'
Common stock issued in exchange for services, shares	'	'	17,004	'	'	'	'
Net loss	-5,519,151	'	'	'	'	'	-5,519,151
Balance at Dec. 31, 2004	-1,856,555	'	9,561	42,706,732	-567,528	'	-44,005,320
Balance, Shares at Dec. 31, 2004	'	'	9,560,634	'	'	'	'
Issuance of common stock	11,267,554	'	1,994	11,265,560	'	'	'
Issuance of common stock, Shares	1,994,556	'	1,994,556	'	'	'	'
Stock based compensation	'	'	'	1,566,147	-1,566,147	'	'
Amortization of stock based compensation	1,952,350	'	'	'	1,952,350	'	'
Common stock issued in exchange for services	1,210	'	'	'	'	'	'
Common stock issued in exchange for services, shares	95,807	'	'	'	'	'	'
Issuance of common stock in lieu of cash compensation	6,853	'	1	6,852	'	'	'
Issuance of common stock in lieu of cash compensation, Shares	1,210	'	1,210	'	'	'	'
Issuance of common stock in exchange for release of accrued liabilities	542,787	'	96	542,691	'	'	'
Issuance of common stock in exchange for release of accrued liabilities, Shares	95,807	'	95,807	'	'	'	'
Net loss	-7,326,557	'	'	'	'	'	-7,326,557
Balance at Dec. 31, 2005	4,586,432	'	11,652	56,087,982	-181,325	'	-51,331,877
Balance, Shares at Dec. 31, 2005	'	'	11,652,207	'	'	'	'
Issuance of common stock	8,124,692	'	1,069	8,123,623	'	'	'
Issuance of common stock, Shares	1,069,699	'	1,069,699	'	'	'	'
Stock based compensation	1,224,430	'	'	1,224,430	'	'	'
Fair value of warrants issued in exchange for licenses and intellectual property	144,867	'	'	144,867	'	'	'
Common stock issued in exchange for services	16,443	'	3	16,440	'	'	'
Common stock issued in exchange for services, shares	2,903	'	2,903	'	'	'	'
Reclassification of deferred compensation due to adoption of SFAS No. 123 ( R)	'	'	'	-181,325	181,325	'	'
Equity instruments issued in connection with settlement agreement	3,294,429	'	48	3,294,381	'	'	'
Equity instruments issued in connection with settlement agreement, Shares	'	'	47,657	'	'	'	'
Common stock issued in exchange for distribution rights and intellectual property	99,997	'	13	99,984	'	'	'
Common stock issued in exchange for distribution rights and intellectual property, Shares	'	'	13,006	'	'	'	'
Net loss	-13,180,646	'	'	'	'	'	-13,180,646
Balance at Dec. 31, 2006	4,310,644	'	12,785	68,810,382	'	'	-64,512,523
Balance, Shares at Dec. 31, 2006	'	'	12,785,472	'	'	'	12,785,472
Issuance of common stock	3,920,716	'	530	3,920,186	'	'	'
Issuance of common stock, Shares	529,432	'	529,432	'	'	'	'
Stock based compensation	931,233	'	'	931,233	'	'	'
Fair value of warrants issued in exchange for licenses and intellectual property	48,289	'	'	48,289	'	'	'
Exercise of stock options	181,040	'	32	181,008	'	'	'
Exercise of stock options, Shares	'	'	31,955	'	'	'	31,955
Warrants issued in connection with notes payable	3,162,488	'	'	3,162,488	'	'	'
Warrants issued in exchange for services	30,559	'	'	30,559	'	'	'
Shares issued in connection with reverse stock split	'	'	279	'	'	'	'
Net loss	-18,067,084	'	'	'	'	'	-18,067,084
Balance at Dec. 31, 2007	-5,482,115	'	13,347	77,084,145	'	'	-82,579,607
Balance, Shares at Dec. 31, 2007	'	'	13,347,138	'	'	'	'
Issuance of common stock	2,118,505	'	1,230	2,117,275	'	'	'
Issuance of common stock, Shares	1,230,280	'	1,230,280	'	'	'	'
Stock based compensation	1,320,995	'	'	1,320,995	'	'	'
Exercise of stock options	79,076	'	62	79,014	'	'	'
Exercise of stock options, Shares	'	'	61,778	'	'	'	'
Warrants issued in connection with notes payable	168,387	'	'	168,387	'	'	'
Warrants issued in exchange for services	251,850	'	'	251,850	'	'	'
Initial public offering of common stock	1,447,829	'	1,100	1,446,729	'	'	'
Initial public offering of common stock, Shares	1,100,000	'	1,100,000	'	'	'	'
Warrants issued in connection with settlement agreement	87,200	'	'	87,200	'	'	'
Net loss	-14,149,401	'	'	'	'	'	-14,149,401
Balance at Dec. 31, 2008	-14,157,674	'	15,739	82,555,595	'	'	-96,729,008
Balance, Shares at Dec. 31, 2008	'	'	15,739,196	'	'	'	'
Issuance of common stock	1,859,822	'	2,682	1,857,140	'	'	'
Issuance of common stock, Shares	'	'	2,680,230	'	'	'	'
Stock based compensation	296,838	'	'	296,838	'	'	'
Common stock issued in exchange for services	45,900	'	45	45,855	'	'	'
Common stock issued in exchange for services, shares	'	'	45,000	'	'	'	'
Exercise of stock options	32,000	'	40	31,960	'	'	'
Exercise of stock options, Shares	'	'	40,000	'	'	'	'
Warrants issued in connection with notes payable	1,913,487	'	'	1,913,487	'	'	'
Subscription receivable	'	'	85	59,451	'	-59,536	'
Subscription receivable, Shares	'	'	85,090	'	'	'	'
Common stock issued in connection with the settlement of accounts payable	456,794	'	519	456,275	'	'	'
Common stock issued in connection with the settlement of accounts payable, Shares	'	'	519,460	'	'	'	'
Common stock issued in connection with issuance of note payable	298,001	'	320	297,681	'	'	'
Common stock issued in connection with issuance of note payable, Shares	'	'	320,000	'	'	'	'
Common stock issued upon conversion of notes payable	262,224	'	606	261,618	'	'	'
Common stock issued upon conversion of notes payable, Shares	'	'	606,708	'	'	'	'
Net loss	-4,435,756	'	'	'	'	'	-4,435,756
Balance at Dec. 31, 2009	-13,428,364	'	20,036	87,775,900	'	-59,536	-101,164,764
Balance, Shares at Dec. 31, 2009	'	'	20,035,684	'	'	'	'
Issuance of common stock	2,399,800	'	11,335	2,328,929	'	59,536	'
Issuance of common stock, Shares	'	'	11,334,705	'	'	'	'
Stock based compensation	248,457	'	'	248,457	'	'	'
Common stock issued in exchange for services	360,032	'	529	359,503	'	'	'
Common stock issued in exchange for services, shares	529,520	'	529,520	'	'	'	'
Warrants issued in connection with notes payable	185,307	'	'	185,307	'	'	'
Subscription receivable	'	'	20	3,780	'	-3,800	'
Subscription receivable, Shares	'	'	20,000	'	'	'	'
Common stock issued in connection with the settlement of accounts payable	412,660	'	831	411,829	'	'	'
Common stock issued in connection with the settlement of accounts payable, Shares	831,526	'	831,526	'	'	'	'
Common stock issued in connection with bank guarantor liabilities	2,965,370	'	4,794	2,960,576	'	'	'
Common stock issued in connection with bank guarantor liabilities, Shares	'	'	4,794,430	'	'	'	'
Net loss	-5,159,456	'	'	'	'	'	-5,159,456
Balance at Dec. 31, 2010	-12,016,194	'	37,545	94,274,281	'	-3,800	-106,324,220
Balance, Shares at Dec. 31, 2010	'	'	37,545,865	'	'	'	'
Issuance of common stock	1,424,800	'	22,184	1,402,616	'	'	'
Issuance of common stock, Shares	22,184,540	'	22,184,540	'	'	'	'
Stock based compensation	409,314	'	'	409,314	'	'	'
Common stock issued in exchange for services	115,035	'	1,000	114,035	'	'	'
Common stock issued in exchange for services, shares	1,000,000	'	1,000,000	'	'	'	'
Equity instruments issued in connection with settlement agreement	317,519	'	4,522	312,997	'	'	'
Equity instruments issued in connection with settlement agreement, Shares	'	'	4,521,700	'	'	'	'
Exercise of stock options	1,632	'	1,983	-351	'	'	'
Exercise of stock options, Shares	1,982,995	'	1,982,995	'	'	'	'
Common stock issued upon conversion of notes payable	1,542,109	'	27,121	1,514,988	'	'	'
Common stock issued upon conversion of notes payable, Shares	27,120,856	'	27,120,856	'	'	'	'
Cancellation of previously issued shares	'	'	-3	3	'	'	'
Cancellation of previously issued shares, Shares	'	'	-3,450	'	'	'	'
Proceeds from common stock subscription	3,800	'	'	'	'	3,800	'
Common stock issued upon conversion of notes payable and accrued interest	1,542,109	'	'	'	'	'	'
Common stock issued upon conversion of notes payable and accrued interest, Shares	27,120,856	'	'	'	'	'	'
Common stock issued in settlement of related party advance	140,000	'	1,273	138,727	'	'	'
Common stock issued in settlement of related party advance, Shares	1,272,730	'	1,272,730	'	'	'	'
Beneficial conversion feature connection with issuance of convertible note	748,545	'	'	748,545	'	'	'
Net loss	-4,697,037	'	'	'	'	'	-4,697,037
Balance at Dec. 31, 2011	-12,010,477	'	95,625	98,915,155	'	'	-111,021,257
Balance, Shares at Dec. 31, 2011	'	'	95,625,236	'	'	'	'
Issuance of common stock	509,800	'	24,085	485,715	'	'	'
Issuance of common stock, Shares	'	'	24,085,718	'	'	'	'
Stock based compensation	76,674	'	'	76,674	'	'	'
Common stock issued in exchange for services	34,600	'	953	33,647	'	'	'
Common stock issued in exchange for services, shares	952,851	'	952,851	'	'	'	'
Preferred stock issued in settlement of forbearance agreement	'	'	'	'	'	'	'
Common stock issued upon conversion of notes payable	720,214	'	51,752	668,462	'	'	'
Common stock issued upon conversion of notes payable, Shares	51,751,138	'	51,751,138	'	'	'	'
Fair value of warrants issued in connection with forbearance agreement	119,023	'	'	119,023	'	'	'
Beneficial conversion feature connection with issuance of convertible note	234,729	'	'	234,739	'	'	'
Common stock issued under "put" agreement	150,000	'	8,948	141,052	'	'	'
Common stock shares issued under "put" agreement	8,797,859	'	8,947,859	'	'	'	'
Common stock issued for accrued liabilities	14,000	'	700	13,300	'	'	'
Common stock issued for accrued liabilities, Shares	700,000	'	700,000	'	'	'	'
Reclassify committed common shares in excess of authorized amount to liability	-427,663,000	'	'	-427,663	'	'	'
Net loss	-4,016,467	'	'	'	'	'	-4,016,467
Balance at Dec. 31, 2012	-14,595,567	'	182,063	100,260,094	'	'	-115,037,724
Balance, Shares at Dec. 31, 2012	'	'	182,062,802	'	'	'	'
Issuance of common stock	865,000	'	50,029	814,971	'	'	'
Issuance of common stock, Shares	50,029,227	'	50,029,227	'	'	'	'
Stock based compensation	125,515	'	'	125,515	'	'	'
Common stock issued in exchange for services	85,151	'	6,220	78,931	'	'	'
Common stock issued in exchange for services, shares	6,220,263	'	6,220,263	'	'	'	'
Common stock issued in settlement of related party notes payable	397,750	'	34,890	362,860	'	'	'
Common stock issued in settlement of related party notes payable, Shares	34,890,348	'	34,890,348	'	'	'	'
Preferred stock issued in settlement of debt	70,000	5,000	'	65,000	'	'	'
Preferred stock issued in settlement of debt, Shares	5,000,000	5,000,000	'	'	'	'	'
Preferred stock issued in settlement of forbearance agreement	274,050	15,000	'	259,050	'	'	'
Preferred stock issued in settlement of forbearance agreement, Shares	15,000,000	15,000,000	'	'	'	'	'
Common stock issued in connection with issuance of note payable	157,216	'	5,656	151,560	'	'	'
Common stock issued in connection with issuance of note payable, Shares	5,656,340	'	5,656,340	'	'	'	'
Proceeds from common stock subscription	215,000	'	'	'	'	215,000	'
Common stock issued under "put" agreement	346,914	'	31,053	315,861	'	'	'
Common stock shares issued under "put" agreement	'	'	31,052,141	'	'	'	'
Common stock issued in connection with issuance of convertible debt	36,250	'	2,500	33,750	'	'	'
Common stock issued in connection with issuance of convertible debt, Shares	2,500,000	'	2,500,000	'	'	'	'
Common stock issued in connection with settlement of debt	793,135	'	57,968	735,167	'	'	'
Common stock issued in connection with settlement of debt, Shares	57,967,906	'	57,967,906	'	'	'	'
Common stock issued in settlement of interest and penalty in connection with convertible debt	150,815	'	9,409	141,406	'	'	'
Common stock issued in settlement of interest and penalty in connection with convertible debt, Shares	9,408,718	'	9,408,718	'	'	'	'
Net loss	-3,143,259	'	'	'	'	'	-3,143,259
Reclassify the fair value of excess committed shares derivative to equity upon common share authorization increase	474,954	'	'	474,954	'	'	'
Balance at Dec. 31, 2013	($13,747,076)	$20,000	$379,788	$103,819,119	'	$215,000	($118,180,983)
Balance, Shares at Dec. 31, 2013	'	20,000,000	379,787,745	'	'	'	'

Statement_of_Stockholders_Defi1

Statement of Stockholders Deficit (Parenthetical) (USD $)	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2008	Dec. 31, 2007	Dec. 31, 2006	Dec. 31, 2005	Dec. 31, 2001	Dec. 31, 2000
Statement Of Stockholders' Deficit [Abstract]	'	'	'	'	'	'	'	'	'
Issuance costs of common stock (in dollars)	$40,000	$2,950	$13,664	$24,325	$150,000	$100,038	$32,507	$98,996	$61,905
Issuance cost of Initial public offering of common stock (in dollars)	'	'	'	$4,327,171	'	'	'	'	'

Statements_of_Cash_Flows

Statements of Cash Flows (USD $)	12 Months Ended		173 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
CASH FLOWS FROM OPERATING ACTIVITIES:	'	'	'
Net loss	($3,143,259)	($4,016,467)	($118,180,983)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'	'
Depreciation and amortization	2,190	14,589	900,104
Bad debt expense	'	'	166,266
Discount on convertible debt	368,682	468,581	1,980,250
Gain on change in fair value of derivative liability	-29,179	-119,795	-123,948
Gain on extinguishment of debt	-1,023,439	'	-1,023,439
Non cash payment of interest	228,657	93,209	499,767
Amortization of warrants issued in exchange for licenses and intellectual property	'	'	5,413,156
Amortization of warrants issued in connection with notes payable	'	95,291	5,437,604
Amortization of loan costs	'	927	1,228,717
Related party notes payable issued for services rendered	500,000	'	500,000
Warrants issued in exchange for services	'	'	285,659
Warrants issued in exchange for forbearance agreement	'	430,213	430,213
Equity instruments issued in connection with R&D agreement	'	'	360,032
Equity instruments issued in connection with settlement agreement	'	'	3,381,629
Common stock issued in connection with accounts payable	2,500	'	759,316
Common stock issued in exchange for services	85,151	34,600	1,567,673
Common stock issued in connection with amounts due to guarantors of Bank of America loan	'	'	69,159
Common stock issued in exchange for distribution rights and intellectual property	'	'	99,997
Preferred stock issued in settlement of forbearance agreement	274,050	'	274,050
Warrants issued in connection with accounts payable	'	'	7,758
Stock based compensation	125,515	76,674	10,076,517
(Increase) decrease in:	'	'	'
Receivables	-18,571	2,153	-21,178
Inventory	62,953	749	'
Prepaid and other current assets	85,251	8,295	33,748
Other assets	'	'	-28,854
Increase (decrease) in:	'	'	'
Accounts payable	-59,059	324,264	3,200,620
Accrued expenses	625,232	1,491,441	7,363,476
Deferred revenue	'	'	465,287
Net cash used in operating activities	-1,913,326	-1,095,276	-74,877,404
CASH FLOWS FROM INVESTING ACTIVITIES:	'	'	'
Acquisitions of property and equipment	-9,425	-933	-909,158
Net cash used by investing activities	-9,425	-933	-909,158
CASH FLOWS FROM FINANCING ACTIVITIES:	'	'	'
Bank overdraft	-89	89	'
Proceeds from issuance of common stock, net	1,426,914	584,800	65,308,689
Proceeds from (payments for) initial public offering of common stock, net	'	'	1,447,829
Proceeds from subordinated related party note	'	'	3,000,000
Payment of note payable	'	'	-3,000,000
Proceeds from notes payable, related party	'	'	505,000
Proceeds from related party advances	215,500	411,492	1,082,992
Proceeds from exercise of stock options	'	'	293,749
Proceeds from notes payable	415,500	63,000	12,036,250
Repayments of notes payable	-88,847	'	-3,622,452
Payment of loan costs	'	'	-1,219,268
Net cash provided in financing activities	1,968,978	1,059,381	75,832,789
Net increase (decrease)	46,227	-36,828	46,227
Cash and cash equivalents, beginning of period	'	36,828	'
Cash and cash equivalents, end of period	46,227	'	46,227
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION	'	'	'
Interest paid	521,742	403,618	2,705,824
Income taxes paid	'	'	'
Non cash financing activities:	'	'	'
Common stock issued in settlement of notes payable	793,135	720,214	5,046,094
Common stock issued in settlement of accounts payable	157,216	14,000	171,216
Common stock issued in settlement of related party notes payable	397,750	'	397,750
Common stock issued in settlement of interest and penalties in connection with convertible debt	150,815	'	150,815
Preferred stock issued in settlement of notes payable	70,000	'	70,000
Reclassification of fair value of excess committed share liability to equity upon common share authorization increase	474,954	'	474,954
Reclassification from notes payable to related party advances	'	$544,267	$544,267

Significant_Accounting_Policie

Significant Accounting Policies	12 Months Ended
	Dec. 31, 2013
Significant Accounting Policies [Abstract]	'
SIGNIFICANT ACCOUNTING POLICIES	'
	NOTE 1 — SIGNIFICANT ACCOUNTING POLICIES
	A summary of the significant accounting policies applied in the presentation of the accompanying financial statements follows:
	Basis and business presentation
	Bioheart, Inc (the “Company”) was incorporated under the laws of the State of Florida in August 1999. The Company is in the development stage, as defined by Accounting Standards Codification subtopic 915-10, Development Stage Entities (“ASC 915-10”) and is the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. To date, the Company has not generated significant sales revenues, has incurred expenses and has sustained losses. Consequently, its operations are subject to all the risks inherent in the establishment of a new business enterprise. For the period from inception through December 31, 2013, the Company has accumulated a deficit through its development stage of $118,180,983.
	Estimates
	The preparation of the financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect certain reported amounts and disclosures. The most significant estimates are those used in determination of derivative liabilities and stock compensation. Accordingly, actual results could differ from those estimates.
	Revenue Recognition
	The Company recognizes revenue in accordance with Accounting Standards Codification subtopic 605-10, Revenue Recognition (“ASC 605-10”) which requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management’s judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded.
	At the time of each transaction, management assesses whether the fee associated with the transaction is fixed or determinable and whether or not collection is reasonably assured. The assessment of whether the fee is fixed or determinable is based upon the payment terms of the transaction. If a significant portion of a fee is due after our normal payment terms or upon implementation or client acceptance, the fee is accounted for as not being fixed or determinable and revenue is recognized as the fees become due or after implementation or client acceptance has occurred. Collectability is assessed based on a number of factors, including past transaction history with the client and the creditworthiness of the client.
	Unbilled revenue is revenue that is recognized but is not currently billable to the customer pursuant to contractual terms. In general, such amounts become billable in accordance with predetermined payment schedules, but recognized as revenue as services are performed. Amounts included in unbilled revenue are expected to be collected within one year and are included within current assets.
	Cash
	The Company considers cash to consist of cash on hand and temporary investments having an original maturity of 90 days or less that are readily convertible into cash.
	Accounts Receivable
	Trade receivables are carried at their estimated collectible amounts. Trade credit is generally extended on a short-term basis; thus trade receivables do not bear interest. Trade accounts receivable are periodically evaluated for collectability based on past credit history with customers and their current financial condition.
	Allowance for Doubtful Accounts
	Any changes to the allowance for doubtful accounts on accounts receivable are charged to operations in amounts sufficient to maintain the allowance for uncollectible accounts at a level management believes is adequate to cover any probable losses. Management determines the adequacy of the allowance based on historical write-off percentages and the current status of accounts receivable. Accounts receivable are charged off against the allowance when collectability is determined to be permanently impaired. As of December 31, 2013 and 2012, allowance for doubtful accounts was $-0-.
	Long-Lived Assets
	The Company follows FASB ASC 360-10-15-3, “Impairment or Disposal of Long-lived Assets,” which established a “primary asset” approach to determine the cash flow estimation period for a group of assets and liabilities that represents the unit of accounting for a long-lived asset to be held and used. Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. Long-lived assets to be disposed of are reported at the lower of carrying amount or fair value less cost to sell. The Company determined that there was no impairment on its long-lived assets during 2013 and 2012.
	Other assets
	During the year ended December 2011, the Company’s management performed an evaluation of its other assets (cost basis investment) for purposes of determining the implied fair value of the asset at December 31, 2011, respectively. In 2011, the test indicated that the recorded remaining book value of its investment exceeded its fair value for the year ended December 31, 2011, as determined by discounted future cash flows. As a result, upon completion of the assessment, management recorded a non-cash impairment charge of $58,695 (unaudited), net of tax during the year ended December 31, 2011 to reduce the carrying value of the investment to $-0- (unaudited). Considerable management judgment is necessary to estimate the fair value. Accordingly, actual results could vary significantly from management’s estimates.
	Property and Equipment
	Property and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings. For financial statement purposes, property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives of 3 to 15 years.
	Income Taxes
	The Company has adopted Accounting Standards Codification subtopic 740-10, Income Taxes (“ASC 740-10”) which requires the recognition of deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the financial statement or tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Temporary differences between taxable income reported for financial reporting purposes and income tax purposes consist primarily of derivative liability and stock compensation accounting versus tax differences.
	Comprehensive Income
	The Company does not have any items of comprehensive income in any of the periods presented.
	Net Loss per Common Share, basic and diluted
	The Company has adopted Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”) specifying the computation, presentation and disclosure requirements of earnings per share information. Basic loss per share has been calculated based upon the weighted average number of common shares outstanding. Stock options and warrants have been excluded as common stock equivalents in the diluted loss per share because their effect is anti-dilutive on the computation. Fully diluted shares outstanding were 344,241,761 and 195,204,110 for the years ended December 31, 2013 and 2012, respectively.
	Stock based compensation
	The Company follows Accounting Standards Codification subtopic 718-10, Compensation (“ASC 718-10”) which requires that all share-based payments to both employees and non-employees be recognized in the income statement based on their fair values. (See note 10)
	As of December 31, 2013, there were outstanding stock options to purchase 23,912,943 shares of common stock, 6,600,443 shares of which were vested.
	Concentrations of Credit Risk
	The Company’s financial instruments that are exposed to a concentration of credit risk are cash and accounts receivable. Effective December 31, 2010 and extending through December 31, 2012, all non-interest-bearing transaction accounts are fully insured by the Federal Deposit Insurance Corporation (FDIC), regardless of the balance of the account. Generally, the Company’s cash and cash equivalents in interest-bearing accounts does not exceed FDIC insurance limits. The financial stability of these institutions is periodically reviewed by senior management.
	As of December 31, 2013, three customers represented 36%, 20% and 20%, aggregate of 76% of the Company’s accounts receivable. As of December 31, 2012, three customers represented 96% of the Company’s accounts receivable
	The Company’s revenues earned from sale of products and services for the year ended December 31, 2013 included 20% of the Company’s total revenues from one customer. For the year ended December 31, 2012, Company’s revenues earned from sale of products and services included 80% of the Company’s total revenues from two customers.
	Reliance on Key Personnel and Consultants
	The Company has three full-time employees and no part-time employees. The Company is heavily dependent on the continued active participation of its two current executive officers, one employee and key consultants. The loss of any of the senior management or key consultants could significantly and negatively impact the business until adequate replacements can be identified and put in place.
	Research and Development
	The Company accounts for research and development costs in accordance with Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved as defined under the applicable agreement. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $626,983, $401,941 and $65,320,035 (unaudited) for the years ended December 31, 2013 and 2012, and from August 12, 1999 (date of inception) to December 31, 2013, respectively.
	Derivative Instrument Liability
	The Company accounts for derivative instruments in accordance with ASC 815, which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value, regardless of hedging relationship designation. Accounting for changes in fair value of the derivative instruments depends on whether the derivatives qualify as hedge relationships and the types of relationships designated are based on the exposures hedged. At December 31, 2013 and 2012, the Company did not have any derivative instruments that were designated as hedges.
	Research Grants
	On November 9, 2010, we received a grant in the amount of $244,500 (unaudited) under the qualifying therapeutic discovery project under section 48D of the Internal Revenue code. We have not received any research grant income in recent years.
	Fair Value
	Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and accrued liabilities, and short-term borrowings, as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed.
	The company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures (“ASC 820-10”) and Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”), which permits entities to choose to measure many financial instruments and certain other items at fair value. Neither of these statements had an impact on the Company’s financial position, results of operations nor cash flows.
	Reclassification
	Certain reclassifications have been made to prior periods’ data to conform with the current year’s presentation. These reclassifications had no effect on reported income or losses.
	Recent Accounting Pronouncements
	There were various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s consolidated financial position, results of operations or cash flows.

Going_Concern_Matters

Going Concern Matters	12 Months Ended
	Dec. 31, 2013
Going Concern Matters [Abstract]	'
GOING CONCERN MATTERS	'
	NOTE 2 — GOING CONCERN MATTERS
	The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the accompanying consolidated financial statements during year ended December 31, 2013, the Company incurred net losses of $3,143,259 and used $1,913,326 in cash for operating activities. These factors among others may indicate that the Company will be unable to continue as a going concern for a reasonable period of time.
	The Company’s existence is dependent upon management’s ability to develop profitable operations and to obtain additional funding sources. There can be no assurance that the Company’s financing efforts will result in profitable operations or the resolution of the Company’s liquidity problems. The accompanying statements do not include any adjustments that might result should the Company be unable to continue as a going concern.
	The Company’s ability to obtain additional debt financing and/or alternative arrangements, with the Guarantors or otherwise, may be limited by the amount of, terms and restrictions of our then current debt. Accordingly, until such time, we will generally be restricted from, among other things, incurring additional indebtedness or liens, with limited exceptions. Additional debt financing, if available, may involve restrictive covenants that limit or further limit our operating and financial flexibility and prohibit us from making distributions to shareholders.

Inventory

Inventory	12 Months Ended
	Dec. 31, 2013
Inventory [Abstract]	'
INVENTORY	'
	NOTE 3 — INVENTORY
	Inventory consists of raw materials in 2012. Costs of raw materials are determined using the FIFO method. Inventory is stated at the lower of costs or market (estimated net realizable value).

Property_and_Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2013
Property and Equipment [Abstract]	'
PROPERTY AND EQUIPMENT	'
	NOTE 4 — PROPERTY AND EQUIPMENT
	Property and equipment as of December 31, 2013 and 2012 is summarized as follows:
		2013			2012
	Laboratory and medical equipment	$	352,358		$	352,358
	Furniture, fixtures and equipment		125,634			130,916
	Computer equipment		39,525			54,414
	Leasehold improvements		362,046			362,046
			879,563			899,734
	Less accumulated depreciation and amortization		(870,508	)		(897,914	)
		$	9,055		$	1,820
	Property and equipment are recorded on the basis of cost. For financial statement purposes, property, plant and equipment are depreciated using the straight-line method over their estimated useful lives.
	Expenditures for repair and maintenance which do not materially extend the useful lives of property and equipment are charged to operations. When property or equipment is sold or otherwise disposed of, the cost and related accumulated depreciation are removed from the respective accounts with the resulting gain or loss reflected in operations. Management periodically reviews the carrying value of its property and equipment for impairment in accordance with the guidance for impairment of long lived assets.

Accrued_Expenses

Accrued Expenses	12 Months Ended
	Dec. 31, 2013
Accrued Expenses [Abstract]	'
ACCRUED EXPENSES	'
	NOTE 5 — ACCRUED EXPENSES
	Accrued expenses consisted of the following as of December 31, 2013 and 2012:
		2013		2012
	License and royalty fees	$	2,122,130	$	1,825,675
	Amounts payable to the Guarantors of the Company’s loan agreement with Bank of America and Seaside Bank, including fees and interest		1,373,775		1,284,705
	Interest payable on notes payable		714,180		1,100,174
	Vendor accruals and other		120,692		120,133
	Employee commissions, compensation, etc.		149,558		400,801
		$	4,480,335	$	4,731,488
	During the year ended December 31, 2013, 1,000,000 shares of common stock at a common market price of $0.0195 were issued to one debt holder in exchange for $500,000 in principal and $598,125 of accrued interest relating to a previously issued note. As a result of the settlement, the Company recognized a gain of $1,078,625 during the year ended December 31, 2013.

Standby_Equity_Distribution_Ag

Standby Equity Distribution Agreement	12 Months Ended
	Dec. 31, 2013
Standby Equity Distribution Agreement [Abstract]	'
STANDBY EQUITY DISTRIBUTION AGREEMENT	'
	NOTE 6 – STANDBY EQUITY DISTRIBUTION AGREEMENT
	On November 2, 2011, the Company and Greystone Capital Partners (“Greystone”) entered into a Standby Equity Distribution Agreement (the “Agreement”).  Pursuant to the Agreement, Greystone has agreed to provide the Company with up to $1,000,000 of funding for the 24-month period following the date February 10, 2012, the registration statement of the Company’s common stock was declared effective by the SEC (the “Equity Line”).
	During this 24-month period, commencing on the date on which the SEC first declared the registration statement effective, the Company may request a draw down under the Equity Line by which the Company would sell shares of its common stock to Greystone, which is obligated to purchase the shares under the Agreement.
	For each share of the Company common stock purchased under the Agreement, Greystone will pay eighty percent (80%) of the average of the lowest daily volume weighted average price for five consecutive trading days immediately preceding Advance Notice (the "Valuation Period") commencing the date an Advance Notice (the "Advance Notice") is delivered to Greystone in a manner provided by the Agreement. Subject to certain limitations and floor price reductions, the Company may, at its sole discretion, issue a Put Notice to Greystone and Greystone will then be irrevocably bound to acquire such shares. The registration statement of the Company's common stock pursuant to the Agreement was declared effective on February 10, 2012 and a Post-Effective Amendment was declared effective on May 7, 2013. On December 1, 2012, the parties to the Equity Line agreed that the Purchase Price be adjusted to seventy-five percent (75%) of the lowest daily volume weighted average price of the Common Stock as quoted by Bloomberg, LP, during the five (5) consecutive Trading Days (as such term is defined in the Equity Line) immediately subsequent to the date of the relevant Advance Notice.
	During the year ended December 31, 2013, the Company issued an aggregate of 31,052,141 shares of its common stock in exchange for $346,914 draw down on the equity line. During the year ended December 31, 2012, the Company “put” 8,797,859 shares of common stock for a total of $150,000.

Notes_Payable

Notes Payable	12 Months Ended
	Dec. 31, 2013
Notes Payable [Abstract]	'
NOTES PAYABLE	'
	NOTE 7 – NOTES PAYABLE
	Notes payable were comprised of the following as of December 31, 2013 and 2012:
		2013			2012
	Seaside Bank note payable.	$	980,000		$	980,000
	August 2008 Unsecured Promissory Note		500,000			1,000,000
	Hunton & Williams notes payable		384,972			384,972
	Asher notes payable		143,000			—
	Fourth Man, LLC note payable		35,000			—
	Total notes payable		2,042,972			2,364,972
	Less unamortized debt discount		(112,131	)		—
	Total notes payable net of unamortized debt discount	$	1,930,841		$	2,364,972
	Seaside Bank
	On October 25, 2010, the Company entered into a Loan Agreement with Seaside National Bank and Trust for a $980,000 loan at 4.25% per annum interest that was used to refinance the Company’s loan with Bank of America. The obligation is guaranteed by certain shareholders of the Company. The Loan Agreement was scheduled to mature on December 23, 2013, however the Company is renewing the loan with Seaside National Bank and Trust during the first quarter of 2014 to extend the maturity date. The loan is not in default as of December 31, 2013.
	August 2008 Unsecured Promissory Note
	On August 20, 2008, the Company borrowed $1.0 million from a third party pursuant to the terms of an unsecured Promissory Note and Agreement. Outstanding principal and interest on the loan, which accrues at the rate of 13.5% per annum, is payable in one balloon payment upon the Company’s repayment of the BlueCrest Loan, which is scheduled to mature in May 2010, however the Company is not obligated to make payments until BlueCrest Loan (See Note 10) is paid off. In the event the Company completes a private placement of its common stock and/or securities exercisable for or convertible into its common stock which generates at least $19.0 million of gross proceeds, the Company may prepay, without penalty, all outstanding principal and interest due under the loan using the same type of securities issued in the subject private placement. Because repayment of the loan could occur within 12 months from the date of the balance sheet, the Company has classified this loan as short term.
	Subject to certain conditions, at the end of each calendar quarter during the time the loan is outstanding, the Company may, but is not required to, pay all or any portion of the interest accrued but unpaid as of such date with shares of its common stock.
	In April 2009, as consideration for the authorization to amend certain documents related to the Note, the Company issued to the Note holder a warrant to purchase 451,053 shares of common stock at an exercise price of $0.5321 per share. The warrant, which became exercisable immediately upon issuance, has a ten year term. This warrant had a fair value of $195,694, which was accounted for as additional paid in capital and reflected as a component of debt discount and has been fully amortized as interest expense ratably over the term of the loan.
	During the year ended December 31, 2013, 1,000,000 shares of common stock were issued to the debt holder valued at $19,500, in exchange for $500,000 in principal and $598,125 of accrued interest relating to a previously issued note resulting in a gain of $1,078,625. A gain of $1,078,625 was included in the net gain on settlement of debt and trade payables on the statement of operations. As of December 31, 2013 the remaining principle of this note was $500,000.
	Hunton & Williams Notes
	At December 31, 2013 and 2012, the Company has two unsecured outstanding notes payable with interest due at maturity. The two notes, $61,150 (11.5% interest per annum) and $323,822 (8% interest per annum) are payable in one balloon payment upon the date the Noteholder provides written demand, however the Company is not obligated to make payments until the Northstar (or successor) Loan is paid off (See Note 10).
	Asher Notes
	2012
	On April 2, 2012, the Company entered into a Securities Purchase Agreement with Asher Enterprises, Inc. (“Asher”), for the sale of an 8% convertible note in the principal amount of $63,000 (the “Note”).
	The Note bears interest at the rate of 8% per annum. All interest and principal was due to be repaid on January 3, 2013. The Note is convertible into common stock, at Asher’s option, at a 42% discount to the average of the three lowest closing bid prices of the common stock during the 10 trading day period prior to conversion. The Company has identified the embedded derivatives related to the Asher Note. These embedded derivatives included certain conversion features and reset provision. The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date of Asher Note and to fair value as of each subsequent reporting date. At the inception of the Asher Note, the Company determined the aggregate fair value of $76,682 of the embedded derivatives.
	The fair value of the embedded derivatives was determined using the Binomial Option Pricing Model based on the following assumptions: (1) dividend yield of 0%; (2) expected volatility of 222.81%, (3) weighted average risk-free interest rate of 0.18%, (4) expected life of 0.76 year, and (5) estimated fair value of the Company’s common stock of $0.0373 per share. The initial fair value of the embedded debt derivative of $76,682 was allocated as a debt discount up to the proceeds of the note ($63,000) with the remainder ($13,682) charged to current period operations as interest expense. For the year ended December 31, 2012, the Company amortized or wrote off $63,000 of debt discount to current period operations as interest expense. During the year ended December 31, 2012, the Company issued 6,297,578 shares of its common stock in settlement of the April 2, 2012 Unsecured Convertible Note and related accrued interest.
	2013
	During the year ended December 31, 2013, the Company entered into a Securities Purchase Agreements with Asher Enterprises, Inc. (“Asher”), for the sale of 8% convertible notes in aggregate principal amount of $255,500 (the “Asher Notes”).
	The Asher Notes bear interest at the rate of 8% per annum. As of the December 31, 2013 all interest and principal must be repaid nine months from the issuance date, the last note due August 7, 2014. The Notes are convertible into common stock, at Asher’s option, at a 42% to 45% discount to the average of the three lowest closing bid prices of the common stock during the 10 trading day period prior to conversion. The Company has identified the embedded derivatives related to the Asher Notes. These embedded derivatives included certain conversion features and reset provision.
	The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date of Asher Notes and to fair value as of each subsequent reporting date which at December 31, 2013 was $207,310. At the inception of the Asher Notes, the Company determined the aggregate fair value of $335,089 of the embedded derivatives.
	The fair value of the embedded derivatives was determined using the Binomial Option Pricing Model based on the following assumptions: (1) dividend yield of 0%; (2) expected volatility of 154.80% to 164.29%, (3) weighted average risk-free interest rate of 0.09% to 0.17%, (4) expected lives of 0.67 to .77 years, and (5) estimated fair value of the Company’s common stock from $0.01 to $0.0373 per share. The initial fair value of the embedded debt derivative of $335,089 was allocated as a debt discount up to the proceeds of the note ($255,500) with the remainder ($79,589) charged to current period operations as interest expense. For the years ended December 31, 2013 and 2012, the Company amortized $162,706 and $63,000 of debt discount to current period operations as interest expense, respectively. As of December 31, 2013 the gross balance of the Asher Notes was $143,000.
	Fourth Man, LLC
	On October 11, 2013, the Company entered into a Securities Purchase Agreement with Fourth Man, LLC. (“Fourth Man”), for the sale of an 8% convertible note in the principal amount of $35,000 (the “Note”).
	The Note bears interest at the rate of 8% per annum. All interest and principal must be repaid on April 10, 2014. The Note is convertible into common stock, at Fourth Man’s option, at a 47% discount to the average of the three lowest closing bid prices of the common stock during the 10 trading day period prior to conversion. The Company has identified the embedded derivatives related to the Fourth Man Note. These embedded derivatives included certain conversion features and reset provision. The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date of Fourth Man Note and to fair value as of each subsequent reporting date. At the inception of the Fourth Man Note, the Company determined the aggregate fair value of $52,894 of the embedded derivatives.
	The fair value of the embedded derivatives was determined using the Binomial Option Pricing Model based on the following assumptions: (1) dividend yield of 0%; (2) expected volatility of 164.29%, (3) weighted average risk-free interest rate of 0.07%, (4) expected life of 0.50 year, and (5) estimated fair value of the Company’s common stock of $0.0121 per share. The initial fair value of the embedded debt derivative of $52,894 was allocated as a debt discount up to the proceeds of the note ($35,000) with the remainder ($17,894) charged to current period operations as interest expense. For the year ended December 31, 2013, the Company amortized $15,663 of debt discount to current period operations as interest expense.

Related_Party_Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2013
Related Party Transactions [Abstract]	'
RELATED PARTY TRANSACTIONS	'
	NOTE 8 — RELATED PARTY TRANSACTIONS
	Advances
	As of December 31, 2013 and 2012, the Company officers and directors have provided advances in the aggregate of $416,198 and $313,448 respectively, for working capital purposes. The advances are unsecured, due on demand and non-interest bearing.
	On August 1, 2013, advances in aggregate of $22,750 were converted into a demand promissory note with 5% interest per annum.  On September 30, 2013, the Company issued 1,995,614 shares of common stock in settlement of the $22,750 promissory note.
	On September 30, 2013, the Company issued 8,771,929 shares of its common stock as payment of $100,000 towards cash advances.
	Notes payable-related party
	Northstar Biotechnology Group, LLC
	On February 29, 2012, a note issued to BlueCrest Master Fund Limited was assigned to Northstar Biotechnology Group, LLC (“Northstar”), owned partly by certain directors and existing shareholders of the Company, including Dr. William P. Murphy Jr., Dr. Samuel Ahn and Charles Hart. At the date of the assignment, the principal amount of the BlueCrest note was $544,267.
	On March 30, 2012, the Company and Northstar agreed to extend until May 1, 2012 the initial payment date for any and all required monthly under the Note, such that the first of the four monthly payments required under the Note will be due and payable on May, 2012 and all subsequent payments will be due on a monthly basis thereafter commencing on June 1, 2012, and to waive any and all defaults and/or events of default under the Note with respect to such payments. As of September 30, 2012, the Company was in default, however, subsequent to September 30, 2012, the Company renegotiated the terms of the Note, Northstar has agreed to suspend the requirement of principal payments by the Company and allow payment of interest-only in common stock.
	On September 21, 2012, the Company issued 5,000,000 common stock purchase warrants to Northstar that was treated as Additional interest expense upon issuance.
	On October 1, 2012, the Company and Northstar entered into a limited waiver and forbearance agreement providing a recapitalized new note balance comprised of all sums due Northstar with a maturity date extended perpetually. The Company agreed to issue 5,000,000 shares of Series A Convertible Preferred Stock and 10,000,000 of common stock in exchange for $210,000 as payment towards outstanding debt, default interest, penalties, professional fees outstanding and due Northstar. In addition, the Company executed a security agreement granting Northstar a lien on all patents, patent applications, trademarks, service marks, copyrights and intellectual property rights of any nature, as well as the results of all clinical trials, know-how for preparing Myoblasts, old and new clinical data, existing approved trials, all right and title to Myoblasts, clinical trial protocols and other property rights.
	In addition, the Company granted Northstar a perpetual license on products as described for resale, relicensing and commercialization outside the United States. In connection with the granted license, Northstar shall pay the Company a royalty of up to 8% on revenues generated.
	Effective October 1, 2012, the effective interest rate was 12.85% per annum.  The parties agreed, as of February 28, 2013, to reduce the interest rate to 7% per annum (see Note 14 below).
	In connection with the consideration paid, Northstar waived, from the effective date through the earlier of termination or expiration of the agreement, satisfaction of the obligations as described in the forbearance agreement. In 2012, 5,000,000 shares of Series A Convertible Preferred Stock were approved to be issued. In addition, the Company is obligated to issue additional preferred stock equal in lieu of payment of cash of accrued and unpaid interest on each six month anniversary of the effective date (October 1, 2012). In lieu of the initial two payments in preferred stock, the parties have determined to modify the voting rights of the Series A Convertible Preferred Stock from 20 votes per share on matters to be voted on by the common stock holders to 25 votes per share on matters to be voted on by the common stock holders and all prior and subsequent payments of interest will be in common stock; payments of common stock for April 1, 2013 and October 1, 2013 were made the fourth quarter of 2013 based on the closing price of the common stock on April 1, 2013 and October 1, 2013 respectively (see Note 14 below).
	As described above, during the year ended December 31, 2013, the Company issued the 5,000,000 shares of Series A Convertible Preferred Stock and the 10,000,000 of common stock described above in exchange for the $210,000 as payment towards outstanding principle of the debt. In addition, the Company issued 15,000,000 shares of Series A Convertible Preferred Stock as a penalty in settlement of the terms of the forbearance agreement. The fair value of the Preferred Stock of $274,050 was included in interest expense for the year ended December 31, 2013.
	The Company is required to issue additional shares of its common stock (as amended), in lieu of cash, each six month anniversary of the effective date for any accrued and unpaid interest.
	On September 30, 2013, the Company issued 8,771,929 shares of its common stock as payment of $100,000 towards cash advances.
	On December 24, 2013, the Company issued 3,915,662 shares of its common stock as payment of accrued interest through June 30, 2013 of $85,447.
	As of December 31, 2013, the principle of this note was $362,000.
	Officer and Director Notes
	At December 31, 2013 and 2012, the Company has outstanding notes payable to officers and directors with interest at 8% per annum due at maturity. The three subordinated notes, $125,000, $100,000 and $140,000 were previously due on October 22, 2012, November 30, 2012 and June 4, 2011 respectively, and are unsecured. The Company is not obligated to make payment until Northstar loan is paid off.
	On October 9, 2012, the Company issued an aggregate of $1,278,324 of promissory notes due October 9, 2013 to officers and directors in settlement of outstanding advances and accrued compensation (currently in default). The promissory notes bear interest of 5% per annum and due at maturity. On September 30, 2013, the Company issued an aggregate of 15,350,876 shares of its common stock in settlement of $175,000 of related party notes payable.  During the year ended December 31, 2013, the Company paid $2,000 of the outstanding promissory notes and the principle balance as of December 31, 2013 is $1,101,324.
	On August 1, 2013, the Company issued an aggregate of $500,000 promissory notes due on demand to officers and employee in settlement of accrued compensation. The promissory notes bear interest of 5% per annum and due at various maturity dates.  During the year ended December 31, 2013, the Company paid off $86,847 of the outstanding promissory notes.  The principle outstanding balance of these notes as of December 31, 2013 is $413,153.
	Subordinated debt, related party
	As of December 31, 2013 and 2012, the Company officers and directors have provided notes in aggregate of $1,500,000. The notes are at from 4.75% to 8% per annum and are due upon payoff of the Northstar note payable described above.
	Sales Transactions
	During the year ended December 31, 2013, the Company entered into several immaterial related party sales transactions with vendors that the Company’s Chief Scientific Officer is a part owner.

Derivative_Liabilities

Derivative Liabilities	12 Months Ended
	Dec. 31, 2013
Derivative Liabilities [Abstract]	'
DERIVATIVE LIABILITIES	'
	NOTE 9 — DERIVATIVE LIABILITIES
	Excessive committed shares
	On December 31, 2012, in connection with the previously issued stock options and warrants, the Company had the possibility of exceeding their common shares authorized when considering the number of possible shares that may be issuable to satisfy settlement provisions of these agreements after consideration of all existing instruments that could be settled in shares. The accounting treatment of derivative financial instruments required that the Company reclassify the derivative from equity to a liability at their fair values as of the date possible issuable shares exceeded the authorized level and at fair value as of each subsequent balance sheet date. Any change in fair value was recorded as non-operating, non-cash income or expense at each reporting date. If the fair value of the derivatives was higher at the subsequent balance sheet date, the Company recorded a non-operating, non-cash charge. If the fair value of the derivatives was lower at the subsequent balance sheet date, the Company recorded non-operating, non-cash income.
	On February 4, 2013, in conjunction with the increase in authorized number of shares to 970,000,000, the Company determined it had adequate authorized shares to settle all of these agreements. As such, the Company adjusted the derivative liability to fair value on February 4, 2013 and reclassified the derivative liability to equity. The fair value of the derivative liability of $474,954 (a non-cash item) as of February 4, 2013 was determined using the Binomial Option Pricing model with the following assumptions: dividend yield: 0%; volatility: 156.52%; risk free rate: 0.38%; and expected life: 3.5 years. The Company recorded a loss on change in derivative liabilities of $84,907 during the year ended December 31, 2013.
	Reset warrants
	On October 1, 2012, in connection with the forbearance agreement with Northstar as discussed in Note 8 above, the Company issued an aggregate of 15,000,000 common stock purchase warrants to purchase the Company’s common stock with an exercise price of $0.014 per share for ten years with anti-dilutive (reset) provisions.
	The Company has identified embedded derivatives related to the issued warrants. These embedded derivatives included certain and anti-dilutive (reset) provisions. The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date and to fair value as of each subsequent reporting date.
	At December 31, 2013, the fair value of the reset provision of $146,855 was determined using the Binomial Option Pricing model with the following assumptions: dividend yield: 0%; volatility: 160.41%; risk free rate: 3.04%; and expected life: 8.75 years. The Company recorded a gain on change in derivative liabilities of $74,324 during the year ended December 31, 2013.
	Convertible notes
	During the year ended December 31, 2013, the Company issued convertible notes (see Note 7 above).
	These notes are convertible into common stock, at holders’ option, at a discount to the market price of the Company’s common stock. The Company has identified the embedded derivatives related to these notes relating to certain anti-dilutive (reset) provisions. These embedded derivatives included certain conversion features. The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date of Asher Note and to fair value as of each subsequent reporting date.
	The fair value of the embedded derivatives at December 31, 2013, in the amount of $256,956, was determined using the Binomial Option Pricing Model based on the following assumptions: (1) dividend yield of 0%; (2) expected volatility of 160.41%, (3) weighted average risk-free interest rate of 0.07 to 0.10%, (4) expected lives of 0.27 to 0.60 years, and (5) estimated fair value of the Company’s common stock of $0.01 per share. The Company recorded a gain on change in derivative liabilities of $39,762 during the year ended December 31, 2013.
	Based upon ASC 840-15-25 (EITF Issue 00-19, paragraph 11) the Company has adopted a sequencing approach regarding the application of ASC 815-40 to its outstanding convertible notes. Pursuant to the sequencing approach, the Company evaluates its contracts based upon earliest issuance date.
	At December 31, 2013, the aggregate derivative liabilities was valued at $403,811, the Company believes an event under the contract that would create an obligation to settle in cash or other current assets is remote and has classified the obligation as a long term liability.

Stockholders_Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2013
Stockholders' Equity [Abstract]	'
STOCKHOLDERS' EQUITY	'
	NOTE 10 – STOCKHOLDERS’ EQUITY
	Preferred stock
	On August 17, 2012, the board of directors designated 5,000,000 shares of preferred stock as Series A Convertible Preferred Stock which was increased to 20,000,000 shares of preferred stock as Series A Convertible Preferred Stock. Each share of preferred stock is convertible into equal number of common shares at the option of the holder; entitled to 20 votes on all matters presented to be voted by the holders of common stock; upon event of liquidation, entitled to amount equal to stated value plus any accrued and unpaid dividends or other fees before distribution to junior securities. In lieu of the initial two payments due to Northstar, the parties have determined to modify the voting rights of the Series A Convertible Preferred Stock from 20 votes per share on matters to be voted on by the common stock holders to 25 votes per share on matters to be voted on by the common stock holders (see Note 8 above).
	During the year ended December 31, 2013, the Company issued an aggregate of 20,000,000 shares of Series A Convertible Preferred Stock for principle payment and settlement of forbearance (see note 8 above).
	Common stock
	On September 19, 2011, the Company amended its Articles of Incorporation to increase the number of authorized shares to 200,000,000, consisting of 5,000,000 $0.001 par value preferred stock and 195,000,000 $0.001 common stock.
	On August 6, 2008, the Company amended its Articles of Incorporation to increase the number of authorized shares of its common stock from 50 million to 75 million shares. This amendment was approved by the Company’s shareholders at the Annual Meeting of Shareholders held on July 30, 2008.
	In September 2007, by way of a written consent, the Company’s shareholders holding a majority of its outstanding shares of common stock, the Company’s shareholders approved an amendment to Bioheart’s Articles of Incorporation, increasing the number of authorized shares of capital stock so that, following the reverse stock split that was effectuated on September 27, 2007, the Company had 50 million shares of common stock authorized with a par value of $0.001 per share and five million shares of preferred stock authorized with a par value of $0.001 per share.
	On February 4, 2013, the Company amended its Articles of Incorporation to increase the number of authorized shares to 970,000,000, consisting of 20,000,000 $0.001 par value preferred stock and 950,000,000 $0.001 common stock.
	On February 22, 2008 the Company completed its initial public offering (“IPO”) pursuant to which it sold 1,100,000 shares of common stock at a price per share of $5.25 for net proceeds of approximately $1.45 million after deducting underwriter discounts of approximately $400,000 and offering costs of approximately $3.92 million. The Consolidated Statement of Cash Flows for the year ended December 31, 2008 reflects the Company’s receipt of approximately $4.24 million of “Proceeds from (payments for) initial public offering of common stock, net”. The $4.24 million cash proceeds figure is approximately $2.79 million higher than the $1.45 million net proceeds figure identified above due to payment of $2.79 million of various offering expenses prior to January 1, 2008.
	During the year ended December 31, 2013, the Company issued 50,029,227 shares of common stock for proceeds of $865,000.
	During the year ended December 31, 2013, the Company issued 31,052,141 shares of common stock issued under its standby equity distribution agreement with Greystone Capital Partners.
	During the year ended December 31, 2013, the Company issued an aggregate of 5,656,340 shares of its common stock for settlement of $82,339 of accounts payable. In connection with the settlement, the Company recorded a loss on settlement of debt of $74,877.
	During the year ended December 31, 2013, the Company issued 2,500,000 shares of its common stock in connection with the issuance of a note payable.
	During the year ended December 31, 2013, the Company issued 57,967,906 shares of its common stock in connection with the settlement and/or conversion of various notes payable.
	During the year ended December 31, 2013, the Company issued 34,890,348 shares of its common stock in connection with the settlement of related party notes payable and advances.
	During the year ended December 31, 2013, the Company issued 9,408,718 shares of its common stock in settlement of interest and penalty in connection with convertible debt.
	During the year ended December 31, 2013, the Company issued 6,220,263 shares of its common stock services rendered valued at $85,151.
	During the year ended December 31, 2012, the Company issued an aggregate of 952,851 shares of its common stock, valued at $34,600, in exchange for services rendered.
	During the year ended December 31, 2012, the Company issued an aggregate of 51,751,138 shares of its common stock in exchange for $720,214 of outstanding notes payable and related accrued interest.
	During the year ended December 31, 2012, the Company issued an aggregate of 700,000 shares of its common stock in exchange for $14,000 of accrued liabilities.
	During the year ended December 31, 2011, the Company issued an aggregate of 1,982,995 shares of its common stock on exercise of options.
	During the year ended December 31, 2011, the Company issued an aggregate of 27,120,856 shares of its common stock in exchange for $1,542,109 of outstanding notes payable and related accrued interest.
	During the year ended December 31, 2011, the Company issued an aggregate of 1,000,000 shares of its common stock, valued at $115,035, in exchange for services rendered.
	During the year ended December 31, 2011, the Company issued an aggregate of 1,272,730 shares of its common stock in settlement of outstanding related party advance in the amount of $140,000.
	In 2010, the Company also sold, in a private placement initiated in 2009, an aggregate of 1,512,890 shares of its common stock and warrants (the “Warrants”) to purchase 453,867 shares of its common stock for aggregate gross cash proceeds of approximately $852,964. The Warrants are (i) exercisable solely for cash at a weighted average exercise price of $0.68 per share, (ii) non-transferable for six months following issuance and (iii) exercisable, in whole or in part, at any time and from time to time during the period commencing on the date that is six months and one day following the date of issuance and ending on the third year anniversary of the date of issuance. (Unaudited)
	In 2010, the Company issued, in connection with the conversion of $1,121,195 of debt an aggregate of 7,459,720 shares of its common stock and warrants (the “Warrants”) to purchase 3,729,860 shares of its common stock. The Warrants are (i) exercisable solely for cash at an exercise price of $0.15 per share, (ii) non-transferable for six months following issuance and (iii) exercisable, in whole or in part, at any time and from time to time during the period commencing on the date that is six months and one day following the date of issuance and ending on the third year anniversary of the date of issuance. The shares were issued under the same terms as the above mentioned private placement and therefore are included in issuance of common stock in the consolidated statement of shareholders deficit. (Unaudited)
	In 2010, the Company also sold, in a private placement, an aggregate of 1,553,885 shares of its common stock for aggregate gross cash proceeds of approximately $234,020. (Unaudited)
	In 2010, the Company also sold, in a private placement, an aggregate of 808,210 shares of its common stock and warrants (the “Warrants”) to purchase 404,105 shares of its common stock for aggregate gross cash proceeds of approximately $135,885. The Warrants are (i) exercisable solely for cash at a weighted average exercise price of $0.20 per share, (ii) non-transferable for six months following issuance and (iii) exercisable, in whole or in part, at any time and from time to time during the period commencing on the date that is six months and one day following the date of issuance and ending on the third year anniversary of the date of issuance. (Unaudited)
	As of December 31, 2010 the Company recorded a Subscription Receivable, under the above mentioned private placement, of 20,000 shares of its common stock and warrants (the “Warrants”) to purchase 10,000 shares of its common stock for aggregate gross cash proceeds of approximately $3,800. The Warrants are (i) exercisable solely for cash at a weighted average exercise price of $0.23 per share, (ii) non-transferable for six months following issuance and (iii) exercisable, in whole or in part, at any time and from time to time during the period commencing on the date that is six months and one day following the date of issuance and ending on the third year anniversary of the date of issuance. (Unaudited)
	In 2010, the Company issued, in connection with services, an aggregate of 529,520 shares of its common stock and warrants (the “Warrants”) to purchase 158,856 shares of its common stock. The Warrants are (i) exercisable solely for cash at a weighted average exercise price of $0.78 per share, (ii) non-transferable for six months following issuance and (iii) exercisable, in whole or in part, at any time and from time to time during the period commencing on the date that is six months and one day following the date of issuance and ending on the third year anniversary of the date of issuance. (Unaudited)
	In 2010, the Company issued an aggregate of 831,526 shares of its common stock, in connection with the exercise of stock options, issued for Accounts Payables. (Unaudited)
	In 2010, the Company issued, in connection with the Bank of America guarantor’s liability of $2,172,000 principal along with accrued expenses, an aggregate of 4,794,430 shares of its common stock and warrants (the “Warrants”) to purchase 1,438,329 shares of its common stock. The Warrants are (i) exercisable solely for cash at an weighted average exercise price of $0.74 per share, (ii) non-transferable for six months following issuance and (iii) exercisable, in whole or in part, at any time and from time to time during the period commencing on the date that is six months and one day following the date of issuance and ending on the third year anniversary of the date of issuance. (Unaudited)
	In December 2009, the Company also sold, in a private placement an aggregate of 255,830 shares of its common stock and warrants (the “Warrants”) to purchase 76,749 shares of its common stock for aggregate gross cash proceeds of approximately $188,996. The Warrants are (i) exercisable solely for cash at a weighted average exercise price of $0.89 per share, (ii) non-transferable for six months following issuance and (iii) exercisable, in whole or in part, at any time and from time to time during the period commencing on the date that is six months and one day following the date of issuance and ending on the third year anniversary of the date of issuance. (Unaudited)
	In 2009, the Company also sold, in a private placement initiated in 2008, an aggregate of 2,509,480 shares of its common stock and warrants (the “Warrants”) to purchase 752,844 shares of its common stock for aggregate gross cash proceeds of approximately $1.74 million. The Warrants are (i) exercisable solely for cash at a weighted average exercise price of $0.83 per share, (ii) non-transferable for six months following issuance and (iii) exercisable, in whole or in part, at any time and from time to time during the period commencing on the date that is six months and one day following the date of issuance and ending on the third year anniversary of the date of issuance. In connection with the private placement, the Company paid to a finder who introduced certain investors to the Company aggregate cash fees of $17,856 and warrants to purchase 26,592 shares of common stock at a weighted average exercise price of $0.89 per share. The warrants issued to the finder have the same terms and conditions as the Warrants issued in the private placement. The 2008 private placement was closed on October 31, 2009, with total capital raised of $3,887,032. (Unaudited)
	In 2008, the Company also sold, in a private placement, an aggregate of 1,230,280 shares of its common stock and warrants (the “Warrants”) to purchase 369,084 shares of its common stock for aggregate gross cash proceeds of approximately $2.14 million. The Warrants are (i) exercisable solely for cash at a weighted average exercise price of $2.09 per share, (ii) non-transferable for six months following issuance and (iii) exercisable, in whole or in part, at any time and from time to time during the period commencing on the date that is six months and one day following the date of issuance and ending on the third year anniversary of the date of issuance. In connection with the private placement, the Company paid to a finder who introduced certain investors to the Company aggregate cash fees of $24,325 and warrants to purchase 24,325 shares of common stock at a weighted average exercise price of $1.95 per share. The warrants issued to the finder have the same terms and conditions as the Warrants issued in the private placement. (Unaudited)
	In 2007, the Company sold 529,432 shares of common stock at a price of $7.69 per share to various investors for net proceeds of approximately $3.9 million. (Unaudited)
	In 2006, the Company sold 1,069,699 shares of common stock at a price of $7.69 per share to various investors. The Company also issued 63,566 shares in exchange for services at a price ranging from $5.67 to $7.69 per share. (Unaudited)
	In 2005, the Company sold 1,994,556 shares of common stock at a price of $5.67 per share to various investors. The Company also issued 1,210 shares in exchange for services and issued 95,807 shares in exchange for debt at a price of $5.67 per share. (Unaudited)
	In 2004, the Company sold 808,570 shares of common stock at a price of $5.67 per share to various investors. The Company also issued 1,854 shares to various vendors in exchange for services valued at $10,500. The Company also issued 15,150 shares to the Company’s Chairman of the Board as compensation for services valued at $85,830. (Unaudited)
	In March 2003, the Company effected a recapitalization. The recapitalization provided two shares of common stock for every one share issued as of that date. The Company’s former Chairman of the Board and founding shareholder, who owned 4,405,541 shares of common stock, did not participate in the recapitalization. The number of shares and prices per share in the accompanying financial statements has been retroactively adjusted to reflect the effect of the recapitalization. (Unaudited)
	After the 2003 recapitalization, the Company sold 561,701 shares of common stock at a price of $5.67 per share to various investors. The Company issued 72,980 shares valued at $416,383 to employees as compensation for services related to the closing of various locations. The Company also issued 4,248 shares to various vendors in exchange for services valued at $24,066 and issued 67,073 shares to the Company’s former Chairman of the Board as compensation for services provided to the Company during 2003 and 2002. The shares were valued based on the underlying market price of the common stock and did not differ materially from the fair value of the common stock issued. (Unaudited)
	In 2002, the Company sold 1,092,883 shares of common stock at a price of $6.47 per share to various investors. The Company also issued 35,137 shares to various vendors in exchange for services valued at $227,503. (Unaudited)
	In 2001, the Company sold 985,668 shares of common stock at a price of $6.47 per share to various investors. The Company also issued 8,291 shares to various vendors in exchange for services valued at $54,001 and issued 81,084 shares to the Company’s Chairman of the Board as compensation for services provided to the Company during 2001. (Unaudited)
	In 2000, the Company sold 1,493,575 shares of common stock at a price of $6.47 per share to various investors. Of the 1,493,575 shares sold in 2000, payment on 77,222 of these shares was not received until January 2001. The Company also issued 7,964 shares to various vendors in exchange for services valued at $52,001. (Unaudited)
	In 1999, the Company’s former Chairman of the Board and founding shareholder contributed $400,000 to the Company in exchange for 4,324,458 shares of common stock. (Unaudited)
	Former Chairman of the Board Paid in and Contributed Capital
	In 2006, the Company’s former Chairman of the Board was issued 2,903 shares of the Company’s common stock at a price of $5.67 per share in exchange for $16,443 of services provided during the year. (Unaudited)
	In 2005, the Company’s former Chairman of the Board was issued 95,807 shares of the Company’s common stock at a price of $5.67 per share in exchange for $542,787 of debt due to travel and other related expenses advanced by the Company’s Chairman of the Board during the previous three years. (Unaudited)
	The Company’s former Chairman of the Board elected not to receive salary payments of $85,830, $130,000 and $250,000 for services provided to the Company during 2004, 2003 and 2002, respectively. Such amounts were converted into 15,150, 22,946 and 44,127 shares of the Company’s common stock at a price of $5.67 per share on December 31, 2004 and 2003, respectively, where the 2003 and 2002 shares were both issued in 2003. The shares were valued based on the underlying market price of the common stock and did not differ materially from the fair value of the common stock issued.
	In 2001, the Company’s former Chairman of the Board also elected not to receive a salary payment or a stock conversion of $250,000 for services provided during 2001.
	In 2000, the Company’s former Chairman of the Board contributed $800,000 to the Company and elected not to receive payment for $250,000 of salary related to services provided to the Company during 2000. Such amounts were recorded as contributed capital during 2000. On June 28, 2001, the Company’s Board of Directors approved the conversion of this contributed capital and salary deferral into 81,084 shares of the Company’s common stock at a price of $12.94 per share.

Stock_option_and_Warrants

Stock option and Warrants	12 Months Ended
	Dec. 31, 2013
Stock Options and Warrants [Abstract]	'
STOCK OPTIONS AND WARRANTS	'
	NOTE 11 — STOCK OPTIONS AND WARRANTS
	Stock Options
	In December 1999, the Board of Directors and shareholders adopted the 1999 Officers and Employees Stock Option Plan, or the Employee Plan, and the 1999 Directors and Consultants Stock Option Plan, or the Director Plan. The Employee Plan and the Director Plan are collectively referred to herein as the Plans. The Plans are administered by the Board of Directors and the Compensation Committee. The objectives of the Plans include attracting and retaining key personnel by encouraging stock ownership in the Company by such persons. In February 2010, the Directors & Consultants Plan was amended to extend the termination date of the Plan to December 1, 2011.
	In April 1, 2013, the Board of Directors approved, subject to shareholder approval, the establishment of the Bioheart 2013 Omnibus Equity Compensation Plan, or the “2013 Omnibus Plan”. The 2013 Omnibus Plan reserves up to fifty million shares of common stock for issuance.
	Effective April 1, 2013, the Board of Directors resolved that stock options granted for the past three years as of February 25, 2013 be repriced for employees, management and board members, at the exercise price of the average of the last 5 trading days’ closing price as of February 25, 2013. Subsequently, this action was rescinded and the repricing date was set for August 5, 2013.
	A summary of options at December 31, 2013 and activity during the year then ended is presented below:
		Shares				Weighted-			Weighted-
						Average			Average
						Exercise Price			Remaining
									Contractual
									Term (in years)
	Options outstanding at January 1, 2012		4,636,318			$	1.2		8.1
	Granted		3,300,000			$	0.04
	Exercised		-			$
	Forfeited/Expired		(82,942	)		$	5.57
	Options outstanding at December 31, 2012		7,853,376			$	0.67		8.2
	Granted		17,400,000			$	0.016		9.9
	Exercised		-
	Forfeited/Expired		(1,340,433	)		$	1.08
	Options outstanding at December 31, 2013		23,912,943			$	0.15		9
	Options exercisable at December 31, 2013		6,600,443			$	0.48		8
	Available for grant at December 31, 2013		32,600,000
	The following information applies to options outstanding and exercisable at December 31, 2013:
				Options Outstanding											Options Exercisable
				Shares				Weighted-				Weighted-			Shares			Weighted-
								Average				Average						Average
								Remaining				Exercise						Exercise
								Contractual				Price						Price
								Term
	$0.00 – $0.70				23,290,000				9.2			$	0.03			5,977,500			$	0.07
	$0.71 – $1.28				162,286				4.4			$	0.8			162,286			$	0.8
	$5.25 – $5.67				435,945				2			$	5.57			435,945			$	5.57
	$7.69				24,712				2.6			$	7.69			24,712			$	7.69
					23,912,943				9			$	0.15			6,600,443			$	0.48
	On January 16, 2012, the Company granted 500,000 employee stock options in connection services rendered at the exercise price of $0.10 per share vesting over four years from the date of issuance.
	The fair values of the employee options issued on January 16, 2012 were determined using the Black Scholes option pricing model with the following assumptions: Dividend yield: 0%; Volatility: 164.79% and Risk free rate: 1.89%.
	On August 6, 2012, the Company granted an aggregate 2,800,000 employee stock options in connection services rendered at the exercise price of $0.03 per share vesting over four years from the date of issuance.
	The fair values of the employee options issued on August 6, 2012 were determined using the Black Scholes option pricing model with the following assumptions: Dividend yield: 0%; Volatility: 164.91% and Risk free rate: 1.59%.
	On August 5, 2013, the Company re-priced options previously issued from 2011 through 2012 for current employees and officers in aggregate of 4,890,000 options with previous exercise prices from $0.03 to $0.21 per share to $0.01694 per share, all other terms remaining unchanged.  The gross change in fair value, determined using the Black Scholes option pricing model, of $1,630 was charged to current period operations.
	On August 1, 2013, the Company issued an aggregate 15,000,000 options to purchase the Company’s common stock at $0.01576 per share to employees, exercisable over 4 years.   The fair value of $245,749, determined using the Black Scholes option pricing model with the following assumptions: Dividend yield: 0%; Volatility: 153.27% and Risk free rate: 2.74%, of which $25,599 was charged to current period operations.
	On September 1, 2013, the Company issued an aggregate 2,400,000 options to purchase the Company’s common stock at $0.01654 per share, respectively; to officers and employees, exercisable immediately. The fair value of $37,823, determined using the Black Scholes option pricing model with the following assumptions: Dividend yield: 0%; Volatility: 150.98% and Risk free rate: 2.78%, was charged to current period operations.
	The fair value of all options vesting during the year ended December 31, 2013 and 2012 of $125,515 and $76,674, respectively, was charged to current period operations.
	Warrants
	A summary of common stock purchase warrants at December 31, 2013 and activity during the year then ended is presented below:
		Shares				Weighted-				Weighted-
						Average				Average
						Exercise				Remaining
						Price				Contractual
										Term (in
										years)
	Outstanding at January 1, 2012		32,610,075			$	0.86				3.8
	Issued		42,396,432			$	0.018				5.78
	Exercised		—			$	0
	Forfeited		-933,185			$	0.76
	Outstanding at December 31, 2012		74,073,322			$	0.37				4.5
	Issued		50,350,536			$	0.016				9.2
	Exercised		—			$
	Expired		-6,345,002			$	0.38
	Outstanding at December 31, 2013		118,078,856			$	0.22				6.3
	Exercisable at December 31, 2013		101,371,743			$	0.13				5.7
	In conjunction with the authorized issuance of common stock, the Company granted approximately 50 million common stock purchase warrants during the year ended December 31, 2013.
	The following information applies to common stock purchase warrants outstanding and exercisable at December 31, 2013:
			Warrants Outstanding											Warrants Exercisable
		Shares				Weighted-				Weighted-			Shares		Weighted-
						Average				Average					Average
						Remaining				Exercise					Exercise
						Contractual				Price					Price
						Term
$0.01 – $0.50			111,829,723				6.3			$	0.03			96,667,060		$	0.03
$0.52 – $0.68			2,699,675				5.3			$	0.58			2,699,675		$	0.58
$0.70 – $1.62			848,176				6			$	0.71			848,176		$	0.71
$5.67 – $7.69			2,701,282				8.9			$	7.55			1,156,832		$	7.35
			118,078,856				6.3			$	0.22			101,371,743		$	0.13
During the year ended December 31, 2012, in connection with the sale of common stock, the Company issued an aggregate of 22,396,432 warrants to purchase the Company’s common stock at an exercise prices from $0.014 to $0.03 per shares exercisable in six months and expiring three years from issuance.
On September 21, 2012, the Company issued 5,000,000 warrants to purchase the Company’s common stock at $0.02 per share, expiring 10 years from the date of issuance as payment of interest.
The fair value of $119,023, determined using the Black Scholes option pricing model with the following assumptions: Dividend yield: 0%; Volatility: 163.45% and Risk free rate: 1.779%, was charged to current period operations.
On October 1, 2012, the Company issued 15,000,000 warrants to purchase the Company’s common stock at $0.014 per share, expiring 10 years from the date of issuance as payment of interest with certain reset provisions.
The fair value of $311,190, determined using the Binomial lattice option pricing model with the following assumptions: Dividend yield: 0%; Volatility: 155.41% and Risk free rate: 1.64%, was charged to current period operations.

Commiments_and_Contingencies

Commiments and Contingencies	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies [Abstract]	'
COMMITMENTS AND CONTINGENCIES	'
	NOTE 12 — COMMITMENTS AND CONTINGENCIES
	Leases
	The Company entered into several operating lease agreements for facilities and equipment. Terms of certain lease arrangements include renewal options, escalation clauses, payment of executory costs such as real estate taxes, insurance and common area maintenance. The landlord has filed a security interest against the assets of the Company.
	In February 2010, the Company amended its facility lease to extend the term of the lease until January 2013.
	In August 2011, the Company amended its facility lease to eliminate excess space. The amendment contains terms similar to the terms of the existing facility lease, including escalation clauses.
	In July 2013, the Company amended its facility lease to extend the term of the lease until July 31, 2014. Approximate annual future minimum lease obligations under non-cancelable operating lease agreements as of December 31, 2013 are as follows:
	Year ending December 31,
	2014	$	48,195
	Total	$	48,195
	Rent expense was $123,216 and $89,507 for the years ended December 31, 2013 and 2012, respectively and $2,102,062 for the cumulative period from August 12, 1999 (date of inception) to December 31, 2013.
	Royalty Payments
	The Company is obligated to pay royalties on commercial sales of certain products that may be developed and sold under various licenses and agreements that have been obtained by the Company.
	The Company has entered into a licensing agreement, which include the potential for royalty payments, as follows:
	William Beaumont Hospital
	In June 2000, the Company entered into an exclusive license agreement to use certain patents for the life of the patents in future projects. The patents expire in 2015. In addition to a payment of $55,000, the Company made to acquire the license, the Company is required to pay an annual license fee of $10,000 and royalties ranging from 2% to 4% of net sales of products that are covered by the patents. In order to maintain the exclusive license rights, the agreement also calls for a minimum annual royalty threshold. The minimum royalty threshold was $200,000 for 2011 and $200,000 for 2010. This minimum royalty threshold will remain $200,000 for 2012 and thereafter. As of December 31, 2013, the Company has not made any payments other than the initial payment to acquire the license. At December 31, 2013 and December 31, 2012, the Company’s liability under this agreement was $2,122,130 and $1,825,675, respectively, which is reflected as a component of accrued expenses on the balance sheets (see Note 5).
	During the year ended December 31, 2013 and 2012, the Company incurred expenses of $210,000, $210,000 respectively, and $2,122,130 from August 12, 1999 (date of inception) to December 31, 2013. The Company has accrued interest for the past due commitment at 2% over the prime rate per the terms of the agreement. The Company has included $2,122,130 in accrued expenses as of December 31, 2013.
	Approximate annual future minimum obligations under this agreement as of December 31, 2013 are as follows:
	Year Ending December 31,
	2014		210,000
	2015		210,000
	Total	$	420,000
	Consulting agreements
	On November 20, 2013, the Company entered into an investment banking agreement with Cassel Salpeter & Co. (“CSC”), who will act as exclusive third party financial advisor in connection with investment banking matters.  The term of the Investment Banking Agreement shall be for a period of twenty four months unless terminated or extended in accordance with its terms. For these services, CSC will receive a one-time $25,000 fee, $5,000 monthly fees and 5,207,630 ten year common stock purchase warrants, exercisable at $.0113 and applicable consideration in the event the closing of a Mezzanine Financing consisting of non-convertible subordinated debt and/or sale of equity securities.  The Company will also reimburse CSC for its reasonable out-of-pocket expenses associated with the services provided pursuant to the Investment Banking Agreement.  As of December 31, 2013, the Company accrued $32,424 under the agreement.
	Contingency for Registration of the Company’s common stock
	The Company believes that it may have issued options to purchase common stock to certain of its employees, directors and consultants in California in violation of the registration or qualification provisions of applicable California securities laws. As a result, the Company intends to make a rescission offer to these persons. The Company will make this offer to all persons who have a continuing right to rescission, which it believes to include two persons. In the rescission offer, in accordance with California law, the Company will offer to repurchase all unexercised options issued to these persons at 77% of the option exercise price multiplied by the number of option shares, plus interest at the rate of 7% from the date the options were granted. Based upon the number of options that were subject to rescission as of December 31, 2009, assuming that all such options are tendered in the rescission offer, the Company estimated that its total rescission liability would be up to approximately $371,000. However, as the Company believes there is only a remote likelihood the rescission offer will be accepted by any of these persons in an amount that would result in a material expenditure by the Company, no liability was recorded as of December 31, 2013 or 2012.
	Litigation
	The Company is subject to other legal proceedings that arise in the ordinary course of business. In the opinion of management, as of December 31, 2013, the amount of ultimate liability with respect to such matters, if any, in excess of applicable insurance coverage, is not likely to have a material impact on the Company’s business, financial position, results of operations or liquidity. However, as the outcome of litigation and other claims is difficult to predict significant changes in the estimated exposures could exist.

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2013
Income Taxes [Abstract]	'
Income Taxes	'
	NOTE 13 — INCOME TAXES
	The Company follows Accounting Standards Codification subtopic 740, Income Taxes (“ASC 740”) which requires the recognition of deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under such method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases using enacted tax rates in effect for the year in which the differences are expected to reverse.
	The difference between income tax expense computed by applying the federal statutory corporate tax rate and actual income tax expense is as follows:
		2013			2012
	Income taxes using U.S. federal statutory rate	$	(1,068,708	)		(1,365,599	)
	State income taxes, net of federal benefit		(108,788	)		(80,708	)
	Stock Option Expirations		78,864			326,995
	Net Operating Loss adjustments		-20,008			196,416
	Nontaxable Gain on Derivative Instrument		(9,921	)		(40,730	)
	Change in Valuation Allowance		1,127,875			974,536
	Other		686			(10,910	)
		$	—		$	—
	At December 31, 2013, the significant components of the deferred tax assets (liabilities) are summarized below:
		2013			2012
	Deferred tax assets:
	Stock Based Compensation	$	4,465,854		$	4,505,907
	Net Operating Losses		35,429,429			34,266,157
	Other		125,317			120,661
	Total deferred tax assets		40,020,600			38,892,725
	Deferred tax liabilities:		—			—
	Total deferred tax liabilities		—			—
	Valuation allowance		40,020,600			38,892,725
	Net deferred tax assets	$	—		$	—
	As of December 31, 2013 and December 31, 2012, the Company had U.S. federal net operating loss carryforwards of approximately $94.2 million and $91.1 million, respectively, which expire at various dates from 2019 through 2033. These net operating loss carryforwards may be used to offset future taxable income and thereby reduce the Company’s U.S. federal income taxes. Section 382 of the Internal Revenue Code of 1986 (the “Code”) imposes an annual limit on the ability of a corporation that undergoes a greater than 50% ownership change to use its net operating loss carry forwards to reduce its tax liability. If in the future the Company issues common stock or additional equity instruments convertible in common shares which result in an ownership change exceeding the 50% limitation threshold imposed by section 382 of the Code, the Company’s net operating loss carry-forwards may be significantly limited as to the amount of use in a particular years. In addition, all or a portion of the Company’s net operating loss carryforwards may expire unutilized.
	As of December 31, 2013 and December 31, 2012, the Company had net operating loss carryforwards for state income tax purposes of approximately $94.2 million and $91.1 million, respectively, which expire at various dates from 2019 through 2033.
	The Company has provided a full valuation allowance against its net deferred tax assets, since in the opinion of management based upon the earnings history of the Company; it is more likely than not that the benefits of these assets will not be realized.
	The Company complies with the provisions of FASB ASC 740-10 in accounting for its uncertain tax positions. ASC 740-10 addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC 740-10, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely that not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. Management has determined that the Company has no significant uncertain tax positions requiring recognition under ASC 740-10.
	The Company is subject to income tax in the U.S., and certain state jurisdictions. The Company has not been audited by the U.S. Internal Revenue Service, or any states in connection with income taxes. The periods from December 31, 2006 to December 31, 2013 remain open to examination by the U.S. Internal Revenue Service, and state tax authorities. In addition, federal and state tax authorities can generally reduce a net operating loss (but not create taxable income) for a period outside the statute of limitations in order to determine the correct amount of net operating loss which may be allowed as a deduction against income for a period within the statute of limitations.
	The Company recognizes interest and penalties related to unrecognized tax benefits, if incurred, as a component of income tax expense.

Fair_Value_Measurement

Fair Value Measurement	12 Months Ended
	Dec. 31, 2013
Fair Value Measurement [Abstract]	'
FAIR VALUE MEASUREMENT	'
	NOTE 14 — FAIR VALUE MEASUREMENT
	The Company adopted the provisions of Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) on January 1, 2008. ASC 825-10 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. ASC 825-10 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 825-10 establishes three levels of inputs that may be used to measure fair value:
	Level 1 – Quoted prices in active markets for identical assets or liabilities.
	Level 2 – Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities.
	Level 3 – Unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities.
	All items required to be recorded or measured on a recurring basis consist of derivative liabilities and are based upon level 3 inputs.
	To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is disclosed and is determined based on the lowest level input that is significant to the fair value measurement.
	Upon adoption of ASC 825-10, there was no cumulative effect adjustment to beginning retained earnings and no impact on the financial statements.
	The carrying value of the Company’s cash and cash equivalents, accounts receivable, accounts payable, short-term borrowings (including convertible notes payable), and other current assets and liabilities approximate fair value because of their short-term maturity.
	As of  December 31, 2013 and 2012, the Company did not have any items that would be classified as level 1 or 2 disclosures.
	The Company recognizes its derivative liabilities as level 3 and values its derivatives using the methods discussed in notes 7 and 9. While the Company believes that its valuation methods are appropriate and consistent with other market participants, it recognizes that the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date. The primary assumptions that would significantly affect the fair values using the methods discussed in Notes 7 and 9 are that of volatility and market price of the underlying common stock of the Company.
	As of December 31, 2013 and 2012, the Company did not have any derivative instruments that were designated as hedges.
	The derivative liability as of December 31, 2013, in the amount of $403,811 has a level 3 classification.
	The following table provides a summary of changes in fair value of the Company’s Level 3 financial liabilities as of December 31, 2013:
		Excess Share			Warrant			Debt
		Derivative			Liability			Derivative
	Balance, December 31, 2011	$	-			-		$	-
	Total (gains) losses
	Initial fair value of debt derivative at note issuance					-			76,862
	Initial fair value of derivative relating to reset warrants		-			311,190			-
	Initial fair value of derivative relating to exceeding authorized common shares		427,663			-			-
	Mark-to-market at December 31, 2012		(37,615	)		(90,011	)		7,651
	Transfers out of Level 3 upon conversion and settlement of notes								(84,513	)
	Balance, December 31, 2012	$	390,048		$	221,179		$	-
	Total (gains) losses
	Initial fair value of debt derivative at note issuance		-			-			673,219
	Mark-to-market at December 31, 2013:		84,906			(74,324	)		(39,761	)
	Transfers out of Level 3 upon increase in authorized shares		(474,954
	Transfers out of Level 3 upon conversion of notes payable		-			-			(376,502	)
	Balance, December 31, 2013	$	-		$	146,855		$	256,956
	Net Gain for the period included in earnings relating to the liabilities held at December 31, 2013	$	(84,906	)	$	74,324		$	39,761
	Fluctuations in the Company’s stock price are a primary driver for the changes in the derivative valuations during each reporting period. The Company’s stock price decreased approximately 50% from December 31, 2012 to December 31, 2013. As the stock price decreases for each of the related derivative instruments, the value to the holder of the instrument generally decreases, therefore decreasing the liability on the Company’s balance sheet. Additionally, stock price volatility is one of the significant unobservable inputs used in the fair value measurement of each of the Company’s derivative instruments. The simulated fair value of these liabilities is sensitive to changes in the Company’s expected volatility. Decreases in expected volatility would generally result in a lower fair value measurement.  A 10 percent change in pricing inputs and changes in volatilities and correlation factors would result in less than a $60,318  change in our Level 3 fair value.

Subsequent_Events

Subsequent Events	12 Months Ended
	Dec. 31, 2013
Subsequent Events [Abstract]	'
SUBSEQUENT EVENTS	'
	NOTE 15 — SUBSEQUENT EVENTS
	Subsequent stock issuances
	In January 2014, the Company issued 1,977,155 shares of its common stock in settlement of 2013 services provided for $12,000 and 2,941,176 shares of its common stock in settlement of $15,000 of outstanding convertible notes payable.
	In February 2014, the Company sold an aggregate of 25,114,500 shares of its common stock for net proceeds of $331,500. In connection with the stock sale, the Company issued an aggregate of 25,114,500 warrants to purchase the Company’s common stock for five years at $0.011 to $0.0214 per share. In addition, the Company issued 1,746,032 shares of its common stock in settlement of $10,000 of outstanding convertible notes payable and issued an aggregate of 3,925,442 shares of its common stock in settlement of $55,000 of common stock subscriptions received in 2013.
	Options granted
	On February 23, 2014, the Company granted an aggregate of 15,000,000 options to purchase the Company’s common stock to an officer and key employee at an exercise price of $0.019 for ten years, vesting annually over four years. In addition, the Company granted 400,000 options to purchase the Company’s common stock to each current Director of the Company who was also a board member in fiscal 2011 at an exercise price of $0.019 per share for ten years, vesting immediately with a cashless exercise provision. Additionally, the Company granted 400,000 options to purchase the Company’s common stock to each current Director of the Company at an exercise price of $0.019 per share for ten years, vesting immediately.
	Option expiry terms
	On February 23, 2013, the Company affirmed that options issued to previous board members of the Company will not cease and will terminate at the earlier of the date of exercise or expiration of the option in accordance to its term.
	Related debt conversions
	On February 23, 2014, the Board of Directors approved the conversion of an aggregate of $300,000 related party notes payable at a conversion price of $0.019 per share
	Subsequent financing
	On January 14, 2014, the Company entered into a Securities Purchase Agreement with Asher Enterprises, Inc. (“Asher”), for the sale of an 8% convertible note in the principal amount of $32,500 (the “Note”).
	The Note bears interest at the rate of 8% per annum. All interest and principal must be repaid on October 16, 2014. The Note is convertible into common stock, at Asher’s option, at a 45% discount to the average of the three lowest closing bid prices of the common stock during the 10 trading day period prior to conversion. In the event the Company prepays the Note in full, the Company is required to pay off all principal, interest and any other amounts owing multiplied by (i) 140% if prepaid during the period commencing on the closing date through 179 days thereafter. After the expiration of 180 days following the date of the Note, the Company has no right of prepayment.
	On February 10, 2014, the Company entered into a Securities Purchase Agreement with Asher Enterprises, Inc. (“Asher”), for the sale of an 8% convertible note in the principal amount of $32,500 (the “Note”).
	The Note bears interest at the rate of 8% per annum. All interest and principal must be repaid on November 12, 2014. The Note is convertible into common stock, at Asher’s option, at a 45% discount to the average of the three lowest closing bid prices of the common stock during the 10 trading day period prior to conversion. In the event the Company prepays the Note in full, the Company is required to pay off all principal, interest and any other amounts owing multiplied by (i) 140% if prepaid during the period commencing on the closing date through 179 days thereafter. After the expiration of 180 days following the date of the Note, the Company has no right of prepayment.
	On February 19, 2014, the Company entered into a Securities Purchase Agreement with Daniel James Management, Inc., for the sale of an 8% convertible note in the principal amount of $35,000 (the “Note”).
	The Note bears interest at the rate of 8% per annum. All interest and principal must be repaid on February 18, 2015. The Note is convertible into common stock, at Asher’s option, at a 47% discount to the lowest daily closing bid price of the common stock during the 10 trading day period prior to conversion. In the event the Company prepays the Note in full, the Company is required to pay off all principal at 150%, interest and any other amounts.

Significant_Accounting_Policie1

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2013
Significant Accounting Policies [Abstract]	'
Basis and business presentation	'
	Basis and business presentation
	Bioheart, Inc (the “Company”) was incorporated under the laws of the State of Florida in August 1999. The Company is in the development stage, as defined by Accounting Standards Codification subtopic 915-10, Development Stage Entities (“ASC 915-10”) and is the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. To date, the Company has not generated significant sales revenues, has incurred expenses and has sustained losses. Consequently, its operations are subject to all the risks inherent in the establishment of a new business enterprise. For the period from inception through December 31, 2013, the Company has accumulated a deficit through its development stage of $118,180,983.
Estimates	'
	Estimates
	The preparation of the financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect certain reported amounts and disclosures. The most significant estimates are those used in determination of derivative liabilities and stock compensation. Accordingly, actual results could differ from those estimates.
Revenue Recognition	'
	Revenue Recognition
	The Company recognizes revenue in accordance with Accounting Standards Codification subtopic 605-10, Revenue Recognition (“ASC 605-10”) which requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management’s judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded.
	At the time of each transaction, management assesses whether the fee associated with the transaction is fixed or determinable and whether or not collection is reasonably assured. The assessment of whether the fee is fixed or determinable is based upon the payment terms of the transaction. If a significant portion of a fee is due after our normal payment terms or upon implementation or client acceptance, the fee is accounted for as not being fixed or determinable and revenue is recognized as the fees become due or after implementation or client acceptance has occurred. Collectability is assessed based on a number of factors, including past transaction history with the client and the creditworthiness of the client.
	Unbilled revenue is revenue that is recognized but is not currently billable to the customer pursuant to contractual terms. In general, such amounts become billable in accordance with predetermined payment schedules, but recognized as revenue as services are performed. Amounts included in unbilled revenue are expected to be collected within one year and are included within current assets.
Cash	'
	Cash
	The Company considers cash to consist of cash on hand and temporary investments having an original maturity of 90 days or less that are readily convertible into cash.
Accounts Receivable	'
	Accounts Receivable
	Trade receivables are carried at their estimated collectible amounts. Trade credit is generally extended on a short-term basis; thus trade receivables do not bear interest. Trade accounts receivable are periodically evaluated for collectability based on past credit history with customers and their current financial condition.
Allowance for Doubtful Accounts	'
	Allowance for Doubtful Accounts
	Any changes to the allowance for doubtful accounts on accounts receivable are charged to operations in amounts sufficient to maintain the allowance for uncollectible accounts at a level management believes is adequate to cover any probable losses. Management determines the adequacy of the allowance based on historical write-off percentages and the current status of accounts receivable. Accounts receivable are charged off against the allowance when collectability is determined to be permanently impaired. As of December 31, 2013 and 2012, allowance for doubtful accounts was $-0-.
Long-Lived Assets	'
	Long-Lived Assets
	The Company follows FASB ASC 360-10-15-3, “Impairment or Disposal of Long-lived Assets,” which established a “primary asset” approach to determine the cash flow estimation period for a group of assets and liabilities that represents the unit of accounting for a long-lived asset to be held and used. Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. Long-lived assets to be disposed of are reported at the lower of carrying amount or fair value less cost to sell. The Company determined that there was no impairment on its long-lived assets during 2013 and 2012.
Other assets	'
	Other assets
	During the year ended December 2011, the Company’s management performed an evaluation of its other assets (cost basis investment) for purposes of determining the implied fair value of the asset at December 31, 2011, respectively. In 2011, the test indicated that the recorded remaining book value of its investment exceeded its fair value for the year ended December 31, 2011, as determined by discounted future cash flows. As a result, upon completion of the assessment, management recorded a non-cash impairment charge of $58,695 (unaudited), net of tax during the year ended December 31, 2011 to reduce the carrying value of the investment to $-0- (unaudited). Considerable management judgment is necessary to estimate the fair value. Accordingly, actual results could vary significantly from management’s estimates.
Property and Equipment	'
	Property and Equipment
	Property and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings. For financial statement purposes, property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives of 3 to 15 years.
Income Taxes	'
	Income Taxes
	The Company has adopted Accounting Standards Codification subtopic 740-10, Income Taxes (“ASC 740-10”) which requires the recognition of deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the financial statement or tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Temporary differences between taxable income reported for financial reporting purposes and income tax purposes consist primarily of derivative liability and stock compensation accounting versus tax differences.
Comprehensive Income	'
	Comprehensive Income
	The Company does not have any items of comprehensive income in any of the periods presented.
Net Loss per Common Share, basic and diluted	'
	Net Loss per Common Share, basic and diluted
	The Company has adopted Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”) specifying the computation, presentation and disclosure requirements of earnings per share information. Basic loss per share has been calculated based upon the weighted average number of common shares outstanding. Stock options and warrants have been excluded as common stock equivalents in the diluted loss per share because their effect is anti-dilutive on the computation. Fully diluted shares outstanding were 344,241,761 and 195,204,110 for the years ended December 31, 2013 and 2012, respectively.
Stock based compensation	'
	Stock based compensation
	The Company follows Accounting Standards Codification subtopic 718-10, Compensation (“ASC 718-10”) which requires that all share-based payments to both employees and non-employees be recognized in the income statement based on their fair values. (See note 10)
	As of December 31, 2013, there were outstanding stock options to purchase 23,912,943 shares of common stock, 6,600,443 shares of which were vested.
Concentrations of Credit Risk	'
	Concentrations of Credit Risk
	The Company’s financial instruments that are exposed to a concentration of credit risk are cash and accounts receivable. Effective December 31, 2010 and extending through December 31, 2012, all non-interest-bearing transaction accounts are fully insured by the Federal Deposit Insurance Corporation (FDIC), regardless of the balance of the account. Generally, the Company’s cash and cash equivalents in interest-bearing accounts does not exceed FDIC insurance limits. The financial stability of these institutions is periodically reviewed by senior management.
	As of December 31, 2013, three customers represented 36%, 20% and 20%, aggregate of 76% of the Company’s accounts receivable. As of December 31, 2012, three customers represented 96% of the Company’s accounts receivable
	The Company’s revenues earned from sale of products and services for the year ended December 31, 2013 included 20% of the Company’s total revenues from one customer. For the year ended December 31, 2012, Company’s revenues earned from sale of products and services included 80% of the Company’s total revenues from two customers.
Reliance on Key Personnel and Consultants	'
	Reliance on Key Personnel and Consultants
	The Company has three full-time employees and no part-time employees. The Company is heavily dependent on the continued active participation of its two current executive officers, one employee and key consultants. The loss of any of the senior management or key consultants could significantly and negatively impact the business until adequate replacements can be identified and put in place.
Research and Development	'
	Research and Development
	The Company accounts for research and development costs in accordance with Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved as defined under the applicable agreement. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $626,983, $401,941 and $65,320,035 (unaudited) for the years ended December 31, 2013 and 2012, and from August 12, 1999 (date of inception) to December 31, 2013, respectively.
Derivative Instrument Liability	'
	Derivative Instrument Liability
	The Company accounts for derivative instruments in accordance with ASC 815, which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value, regardless of hedging relationship designation. Accounting for changes in fair value of the derivative instruments depends on whether the derivatives qualify as hedge relationships and the types of relationships designated are based on the exposures hedged. At December 31, 2013 and 2012, the Company did not have any derivative instruments that were designated as hedges.
Research Grants	'
	Research Grants
	On November 9, 2010, we received a grant in the amount of $244,500 (unaudited) under the qualifying therapeutic discovery project under section 48D of the Internal Revenue code. We have not received any research grant income in recent years.
Fair Value	'
	Fair Value
	Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and accrued liabilities, and short-term borrowings, as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed.
	The company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures (“ASC 820-10”) and Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”), which permits entities to choose to measure many financial instruments and certain other items at fair value. Neither of these statements had an impact on the Company’s financial position, results of operations nor cash flows.
Reclassification	'
	Reclassification
	Certain reclassifications have been made to prior periods’ data to conform with the current year’s presentation. These reclassifications had no effect on reported income or losses.
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements
	There were various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s consolidated financial position, results of operations or cash flows.

Property_and_Equipment_Tables

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2013
Property and Equipment [Abstract]	'
Property and equipment	'
		2013			2012
	Laboratory and medical equipment	$	352,358		$	352,358
	Furniture, fixtures and equipment		125,634			130,916
	Computer equipment	39,525			54,414
	Leasehold improvements		362,046			362,046
			879,563			899,734
	Less accumulated depreciation and amortization		(870,508	)		(897,914	)
		$	9,055		$	1,820

Accrued_Expenses_Tables

Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2013
Accrued Expenses [Abstract]	'
Accrued expenses	'
		2013		2012
	License and royalty fees	$	2,122,130	$	1,825,675
	Amounts payable to the Guarantors of the Company’s loan agreement with Bank of America and Seaside Bank, including fees and interest		1,373,775		1,284,705
	Interest payable on notes payable		714,180		1,100,174
	Vendor accruals and other		120,692		120,133
	Employee commissions, compensation, etc.		149,558		400,801
		$	4,480,335	$	4,731,488

Notes_Payable_Tables

Notes Payable (Tables)	12 Months Ended
	Dec. 31, 2013
Notes Payable [Abstract]	'
Summary of notes payable	'
		2013			2012
	Seaside Bank note payable.	$	980,000		$	980,000
	August 2008 Unsecured Promissory Note		500,000			1,000,000
	Hunton & Williams notes payable		384,972			384,972
	Asher notes payable		143,000			—
	Fourth Man, LLC note payable		35,000			—
	Total notes payable		2,042,972			2,364,972
	Less unamortized debt discount		(112,131	)		—
	Total notes payable net of unamortized debt discount	$	1,930,841		$	2,364,972

Stock_option_and_Warrants_Tabl

Stock option and Warrants (Tables)	12 Months Ended
	Dec. 31, 2013																				Dec. 31, 2012
Stock Options and Warrants [Abstract]	'																				'
Summary of options and activity	'																				'
			Shares				Weighted-			Weighted-												Shares			Weighted-		Weighted-
							Average			Average															Average		Average
							Exercise Price			Remaining															Exercise Price		Remaining
										Contractual																	Contractual
										Term (in years)																	Term (in years)
																					Options outstanding at January 1, 2011		2,158,447		$	2.79		6.8
	Options outstanding at January 1, 2012			4,636,318			$	1.2		8.1											Granted		4,620,092		$	0.057
	Granted			3,300,000			$	0.04													Exercised		(1,982,995	)	$	0.001
	Exercised			-			$														Forfeited/Expired		(159,226	)	$	1.8
	Forfeited/Expired			(82,942	)		$	5.57													Options outstanding at December 31, 2011		4,636,318		$	1.2		8.1
	Options outstanding at December 31, 2012			7,853,376			$	0.67		8.2											Granted		3,300,000		$	0.04
	Granted			17,400,000			$	0.016		9.9											Exercised
	Exercised			-																	Forfeited/Expired		(82,942	)	$	5.57
	Forfeited/Expired			(1,340,433	)		$	1.08													Options outstanding at December 31, 2012		7,853,376		$	0.67		8.2
	Options outstanding at December 31, 2013			23,912,943			$	0.15		9											Options exercisable at December 31, 2012		3,694,199		$	1.32
	Options exercisable at December 31, 2013			6,600,443			$	0.48		8											Available for grant at December 31, 2012		0
	Available for grant at December 31, 2013			32,600,000
Options outstanding and exercisable for stock-based payment awards	'																				'
					Options Outstanding											Options Exercisable						Options Outstanding							Options Exercisable
					Shares				Weighted-				Weighted-		Shares			Weighted-
									Average				Average					Average				Shares			Weighted-		Weighted-		Shares		Weighted-
									Remaining				Exercise					Exercise							Average		Average				Average
									Contractual				Price					Price							Remaining		Exercise				Exercise
									Term																Contractual		Price				Price
																									Term
	$	0.00 – $0.70				23,290,000				9.2			$	0.03			5,977,500		$	0.07	$0.00 – $0.70		6,794,360			8.9	$	0.12		2,591,394		$	0.17
	$	0.71 – $1.28				162,286				4.4			$	0.8			162,286		$	0.8	$0.71 – $1.28		324,471			5.3	$	0.77		377,260		$	0.76
	$	5.25 – $5.67				435,945				2			$	5.57			435,945		$	5.57	$5.25 – $5.67		688,177			2.7	$	5.57		679,177		$	5.57
	$	7.69				24,712				2.6			$	7.69			24,712		$	7.69	$7.69		39,572			3.7	$	7.69		39,572		$	7.69
						23,912,943				9			$	0.15			6,600,443		$	0.48	$8.47		6,796			4.3	$	8.47		6,796		$	8.47
																							7,853,376			8.2	$	0.67		3,694,199		$	1.32
Summary of warrants and activity	'																				'
			Shares				Weighted-				Weighted-											Shares			Weighted-		Weighted-
							Average				Average														Average		Average
							Exercise				Remaining														Exercise		Remaining
							Price				Contractual														Price		Contractual
											Term (in																Term
											years)																(in years)
																					Outstanding at January 1, 2011		13,920,729		$	1.98		5.8
	Outstanding at January 1, 2012			32,610,075			$	0.86				3.8									Issued		20,817,034		$	0.07
	Issued			42,396,432			$	0.018				5.78									Exercised		—		$	0
	Exercised			—			$	0													Forfeited		(2,127,688	)	$	0.69
	Forfeited			-933,185			$	0.76													Outstanding at December 31, 2011		32,610,075		$	0.86		3.8
	Outstanding at December 31, 2012			74,073,322			$	0.37				4.5									Issued		42,396,432		$	0.018		5.78
	Issued			50,350,536			$	0.016				9.2									Exercised		—		$
	Exercised			—			$														Expired		(933,185	)	$			0.76
	Expired			-6,345,002			$	0.38													Outstanding at December 31, 2012		74,073,322		$	0.37		4.5
	Outstanding at December 31, 2013			118,078,856			$	0.22				6.3									Exercisable at December 31, 2012		72,528,872		$	0.22		4.5
	Exercisable at December 31, 2013			101,371,743			$	0.13				5.7
Warrants outstanding and exercisable	'																				'
					Warrants Outstanding											Warrants Exercisable						Warrants Outstanding							Warrants Exercisable
					Shares				Weighted-				Weighted-			Shares		Weighted-				Shares			Weighted-		Weighted-		Shares		Weighted-
									Average				Average					Average							Average		Average				Average
									Remaining				Exercise					Exercise							Remaining		Exercise				Exercise
									Contractual				Price					Price							Contractual		Price				Price
									Term																Term
																					0.01 – $0.50		65,623,152			4.4	$	0.04		65,623,152		$	0.04
	$	0.01 – $0.50				111,829,723				6.3			$	0.03			96,667,060		$	0.03	0.52 – $0.68		3,481,127			5	$	0.59		3,481,127		$	0.59
	$	0.52 – $0.68				2,699,675				5.3			$	0.58			2,699,675		$	0.58	0.70 – $1.62		2,122,761			2.9	$	0.76		2,122,761		$	0.76
	$	0.70 – $1.62				848,176				6			$	0.71			848,176		$	0.71	3.60 – $4.93		105,000			0.7	$	4.87		105,000		$	4.87
	$	5.67 – $7.69				2,701,282				8.9			$	7.55			1,156,832		$	7.35	5.67 – $7.69		2,741,282			9.7	$	7.52		1,196,832		$	7.31
						118,078,856				6.3			$	0.22			101,371,743		$	0.13			74,073,322			4.5	$	0.37		72,528,872		$	0.22

Commiments_and_Contingencies_T

Commiments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies [Abstract]	'
Schedule of future minimum lease obligations under non cancelable operating lease agreements	'
	Year ending December 31,
	2014			$	48,195
	Total			$	48,195
Future minimum obligations under the agreement	'
	Year Ending December 31,
	2014		210,000
	2015		210,000
	Total	$	420,000

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2013
Income Taxes [Abstract]	'
Schedule of difference between income tax expense computed by applying the federal statutory corporate tax rate and actual income tax expense	'
				2013			2012
	Income taxes using U.S. federal statutory rate			$	(1,068,708	)		(1,365,599	)
	State income taxes, net of federal benefit				(108,788	)		(80,708	)
	Stock Option Expirations				78,864			326,995
	Net Operating Loss adjustments				-20,008			196,416
	Nontaxable Gain on Derivative Instrument				(9,921	)		(40,730	)
	Change in Valuation Allowance				1,127,875			974,536
	Other				686			(10,910	)
				$	—		$	—
Components of the deferred tax assets (liabilities)	'
		2013			2012
	Deferred tax assets:
	Stock Based Compensation	$	4,465,854		$	4,505,907
	Net Operating Losses		35,429,429			34,266,157
	Other		125,317			120,661
	Total deferred tax assets		40,020,600			38,892,725
	Deferred tax liabilities:		—			—
	Total deferred tax liabilities		—			—
	Valuation allowance		40,020,600			38,892,725
	Net deferred tax assets	$	—		$	—

Fair_Value_Measurement_Tables

Fair Value Measurement (Tables)	12 Months Ended
	Dec. 31, 2013
Fair Value Measurement [Abstract]	'
Summary of changes in fair value of the Company's Level 3 financial liabilities	'
		Excess Share			Warrant			Debt
		Derivative			Liability			Derivative
	Balance, December 31, 2011	$	-			-		$	-
	Total (gains) losses
	Initial fair value of debt derivative at note issuance					-			76,862
	Initial fair value of derivative relating to reset warrants		-			311,190			-
	Initial fair value of derivative relating to exceeding authorized common shares		427,663			-			-
	Mark-to-market at December 31, 2012		(37,615	)		(90,011	)		7,651
	Transfers out of Level 3 upon conversion and settlement of notes								(84,513	)
	Balance, December 31, 2012	$	390,048		$	221,179		$	-
	Total (gains) losses
	Initial fair value of debt derivative at note issuance		-			-			673,219
	Mark-to-market at December 31, 2013:		84,906			(74,324	)		(39,761	)
	Transfers out of Level 3 upon increase in authorized shares		(474,954
	Transfers out of Level 3 upon conversion of notes payable		-			-			(376,502	)
	Balance, December 31, 2013	$	-		$	146,855		$	256,956
	Net Gain for the period included in earnings relating to the liabilities held at December 31, 2013	$	(84,906	)	$	74,324		$	39,761

Significant_Accounting_Policie2

Significant Accounting Policies (Details) (USD $)	1 Months Ended	12 Months Ended			173 Months Ended
	Nov. 30, 2010	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013
		Employees
Significant Accounting Policies (Textual)	'	'	'	'	'
Carrying value of investment after impairment charges	'	'	'	$0	'
Deficit accumulated during development stage	'	118,180,983	115,037,724	'	118,180,983
Allowance for doubtful accounts	'	0	0	'	0
Non cash impairment charges of investment	'	'	'	58,695	58,695
Property and equipment, estimated useful lives	'	'3 to 15 years	'	'	'
Number of fully dilutive outstanding shares	'	344,241,761	195,204,110	'	'
Option outstanding to purchase common stock	'	23,912,943	'	'	23,912,943
Options vested	'	6,600,443	'	'	6,600,443
Number of full time employees	'	3	'	'	'
Number of part time employees	'	0	'	'	'
Research and development expense	'	626,983	401,941	'	65,320,035
Research grant approval amount	$244,500	'	'	'	'
Customer Concentration Risk [Member]	'	'	'	'	'
Significant Accounting Policies (Textual)	'	'	'	'	'
Concentration Risk, Percentage	'	'	80.00%	'	'
Number of customer accounted for accounts receivable	'	'	2	'	'
Revenues earned from sale of products and services percentage	'	20.00%	'	'	'
Number of customers accounted for revenue	'	1	'	'	'
Accounts Receivable [Member] | Customer Concentration Risk [Member]	'	'	'	'	'
Significant Accounting Policies (Textual)	'	'	'	'	'
Concentration Risk, Percentage	'	76.00%	96.00%	'	'
Number of customer accounted for accounts receivable	'	3	3	'	'
Accounts Receivable [Member] | Customer One [Member] | Customer Concentration Risk [Member]	'	'	'	'	'
Significant Accounting Policies (Textual)	'	'	'	'	'
Concentration Risk, Percentage	'	36.00%	'	'	'
Accounts Receivable [Member] | Customer Two [Member] | Customer Concentration Risk [Member]	'	'	'	'	'
Significant Accounting Policies (Textual)	'	'	'	'	'
Concentration Risk, Percentage	'	20.00%	'	'	'
Accounts Receivable [Member] | Customer Three [Member] | Customer Concentration Risk [Member]	'	'	'	'	'
Significant Accounting Policies (Textual)	'	'	'	'	'
Concentration Risk, Percentage	'	20.00%	'	'	'

Going_Concern_Matters_Details

Going Concern Matters (Details) (USD $)	12 Months Ended		173 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Going Concern Matters (Textual)	'	'	'
Net loss before income taxes	($3,143,259)	($4,016,467)	($118,180,983)
Net Cash Provided by (Used in) Operating Activities, Continuing Operations	($1,913,326)	($1,095,276)	($74,877,404)

Property_and_Equipment_Details

Property and Equipment (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Property and equipment	'	'
Laboratory and medical equipment	$352,358	$352,358
Furniture, fixtures and equipment	125,634	130,916
Computer equipment	39,525	54,414
Leasehold improvements	362,046	362,046
Property and equipment, Gross	879,563	899,734
Less accumulated depreciation and amortization	-870,508	-897,914
Property and equipment, net	$9,055	$1,820

Accrued_Expenses_Details

Accrued Expenses (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Accrued expenses	'	'
License and royalty fees	$2,122,130	$1,825,675
Amounts payable to the Guarantors of the Company's loan agreement with Bank of America and Seaside Bank, including fees and interest	1,373,775	1,284,705
Interest payable on notes payable	714,180	1,100,174
Vendor accruals and other	120,692	120,133
Employee commissions, compensation, etc.	149,558	1,033,330
Accrued expenses, Total	$4,480,335	$4,731,488

Accrued_Expenses_Details_Textu

Accrued Expenses (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2010
Accrued Expenses Line Items [Line Items]	'	'
Amount of debt exchanged for shares	'	$1,121,195
Shares issued in conversion of debt	'	7,459,720
Accrued interest	598,125	'
Gain loss on settlement of note payable	1,078,625	'
Common Stock [Member]	'	'
Accrued Expenses Line Items [Line Items]	'	'
Amount of debt exchanged for shares	$500,000	'
Shares issued in conversion of debt	1,000,000	'
Common market price	$0.02	'
Number of debt holder	1	'

Standby_Equity_Distribution_Ag1

Standby Equity Distribution Agreement (Details) (USD $)	1 Months Ended	12 Months Ended
	Nov. 30, 2011	Dec. 31, 2013	Dec. 31, 2012
Standby Equity Distribution Agreement (Textual)	'	'	'
Funds contributed by Greystone	$1,000,000	'	'
Period for which funding is provided	'24 months	'	'
Transaction description of agreement with affiliates	'	'For each share of the Company common stock purchased under the Agreement, Greystone will pay eighty percent (80%) of the average of the lowest daily volume weighted average price for five consecutive trading days immediately preceding Advance Notice (the "Valuation Period") commencing the date an Advance Notice (the "Advance Notice") is delivered to Greystone in a manner provided by the Agreement.	'
Description of purchase price adjustment under equity line	'	'The parties to the Equity Line agreed that the Purchase Price be adjusted to seventy-five percent (75%) of the lowest daily volume weighted average price of the Common Stock as quoted by Bloomberg, LP, during the five (5) consecutive Trading Days (as such term is defined in the Equity Line) immediately subsequent to the date of the relevant Advance Notice.	'
Aggregate common stock share issued	'	31,052,141	'
Amount draw down on the equity line due to issuance of common stock	'	346,914	'
Common stock shares issued under "put" agreement	'	'	8,797,859
Common stock issued under "put" agreement	'	$346,914	$150,000

Notes_Payable_Details

Notes Payable (Details) (USD $)

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Oct. 25, 2010

Dec. 31, 2013

Dec. 31, 2012

Aug. 20, 2008

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Seaside Bank note payable [Member]

Seaside Bank note payable [Member]

Seaside Bank note payable [Member]

August Unsecured Promissory Note [Member]

August Unsecured Promissory Note [Member]

August Unsecured Promissory Note [Member]

Hunton & Williams notes payable [Member]

Hunton & Williams notes payable [Member]

Asher notes payable [Member]

Asher notes payable [Member]

Fourth Man, LLC note payable [Member]

Fourth Man, LLC note payable [Member]

Summary of notes payable

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total notes payable

$2,042,972

$2,364,972

$980,000

$980,000

$980,000

$500,000

$1,000,000

$1,000,000

$384,972

$384,972

$143,000

'

$35,000

'

Less unamortized debt discount

-112,131

'

'

'

'

'

'

'

'

'

'

'

'

'

Total notes payable net of unamortized debt discount

$1,930,841

$2,364,972

'

'

'

'

'

'

'

'

'

'

'

'

Notes_Payable_Details_Textual

Notes Payable (Details Textual) (USD $)

12 Months Ended

173 Months Ended

0 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2013

Aug. 01, 2013

Oct. 25, 2010

Dec. 31, 2013

Dec. 31, 2012

Aug. 20, 2008

Apr. 30, 2009

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Apr. 02, 2012

Dec. 31, 2013

Oct. 11, 2013

Dec. 31, 2012

Seaside Bank note payable [Member]

Seaside Bank note payable [Member]

Seaside Bank note payable [Member]

August 2008 Unsecured Promissory Note [Member]

August 2008 Unsecured Promissory Note [Member]

August 2008 Unsecured Promissory Note [Member]

August 2008 Unsecured Promissory Note [Member]

August 2008 Unsecured Promissory Note [Member]

August 2008 Unsecured Promissory Note [Member]

Hunton & Williams notes payable [Member]

Hunton & Williams notes payable [Member]

Hunton & Williams notes payable [Member]

Hunton & Williams notes payable [Member]

Asher notes payable [Member]

Asher notes payable [Member]

Asher notes payable [Member]

Fourth Man, LLC note payable [Member]

Fourth Man, LLC note payable [Member]

Fourth Man, LLC note payable [Member]

Maximum [Member]

Minimum [Member]

Notes_Payable

Notes_Payable

Note payable one [Member]

Note payable two [Member]

Notes Payable (Textual)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Notes payable

$2,042,972

$2,364,972

'

'

$2,042,972

'

$980,000

$980,000

$980,000

$1,000,000

'

$500,000

$1,000,000

'

'

$384,972

$384,972

'

'

$143,000

'

'

$35,000

'

'

Effective interest rate

'

'

'

'

'

5.00%

4.25%

'

'

13.50%

'

'

'

'

'

'

'

11.50%

8.00%

8.00%

'

8.00%

'

8.00%

'

Loan expiration date

'

'

'

'

'

'

23-Dec-13

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt instrument, Maturity date

'

'

'

'

'

'

'

'

'

31-May-10

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Gross proceeds from private placement

'

'

'

'

'

'

'

'

'

19,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Occurrence period of repayment of loan

'

'

'

'

'

'

'

'

'

'Within 12 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrant issued to purchase common stock

'

'

'

'

'

'

'

'

'

'

451,053

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrant exercise price

'

'

'

'

'

'

'

'

'

'

$0.53

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrant expected term

'

'

'

'

'

'

'

'

'

'

'10 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value of warrant issued

'

'

'

'

'

'

'

'

'

'

195,694

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common shares issued in conversion of debt

'

'

'

7,459,720

'

'

'

'

'

'

'

1,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Amount of debt exchanged for shares

'

'

'

1,121,195

'

'

'

'

'

'

'

19,500

'

'

'

'

'

'

'

'

'

'

'

'

'

Accrued interest

598,125

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Gain loss on settlement of note payable

1,078,625

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Notes payable, Principle value

'

'

'

'

'

'

'

'

'

'

'

500,000

'

'

'

'

'

'

'

255,500

'

63,000

'

35,000

'

Number of outstanding notes payable

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2

2

'

'

'

'

'

'

'

'

Outstanding notes payable

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

61,150

323,822

'

'

'

'

'

'

Description of note payable

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'The Notes are convertible into common stock, at Asher's option, at a 42% to 45% discount to the average of the three lowest closing bid prices of the common stock during the 10 trading day period prior to conversion.

'The Note is convertible into common stock, at Asher's option, at a 42% discount to the average of the three lowest closing bid prices of the common stock during the 10 trading day period prior to conversion. The Company has identified the embedded derivatives related to the Asher Note.

'

'The Note is convertible into common stock, at Fourth Man's option, at a 47% discount to the average of the three lowest closing bid prices of the common stock during the 10 trading day period prior to conversion.

'

'

Fair value of embedded derivatives

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

335,089

76,682

'

52,894

'

'

Dividend yield

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.00%

0.00%

'

0.00%

'

'

Expected volatility

'

'

'

'

'

'

'

'

'

'

'

'

'

164.29%

154.80%

'

'

'

'

'

222.81%

'

164.29%

'

'

Weighted average risk-free interest rate

'

'

'

'

'

'

'

'

'

'

'

'

'

0.17%

0.09%

'

'

'

'

'

0.18%

'

0.07%

'

'

Expected lifes

'

'

'

'

'

'

'

'

'

'

'

'

'

'9 months 7 days

'8 months 1 day

'

'

'

'

'

'9 months 4 days

'

'6 months

'

'

Estimated fair value of the Company's common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.04

$0.01

'

'

'

'

'

$0.04

'

$0.01

'

'

Recorded fair value of derivatives and faire value of each subsequent reporting date

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

207,310

'

'

'

'

'

Amortization of debt discount

368,682

468,581

'

'

1,980,250

'

'

'

'

'

'

'

'

'

'

'

'

'

'

255,500

63,000

'

35,000

'

'

Interest expense

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

79,589

13,682

'

17,894

'

'

Issuance of common stock in settlement of the convertible note and related accrued interest

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6,297,578

'

'

'

'

Outstanding principal amount of debt

413,153

'

'

'

413,153

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock, Value, Subscriptions

215,000

'

'

'

215,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt discount attributed to beneficial conversion feature and common stock issued in amount

'

234,729

748,545

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Notes payable, related party

1,500,000

1,500,000

'

'

1,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amortization of financing costs

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$162,706

$63,000

'

$15,663

'

'

Related_Party_Transaction_Deta

Related Party Transaction (Details) (USD $)

12 Months Ended

1 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

Dec. 31, 2013

Dec. 31, 2010

Sep. 30, 2013

Aug. 01, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 24, 2013

Sep. 30, 2013

Dec. 31, 2013

Oct. 05, 2012

Feb. 28, 2013

Oct. 31, 2012

Sep. 30, 2012

Dec. 31, 2013

Sep. 30, 2013

Oct. 01, 2012

Feb. 29, 2012

Dec. 31, 2002

Sep. 30, 2013

Mar. 31, 2012

Oct. 09, 2012

Sep. 30, 2013

Dec. 31, 2013

Aug. 01, 2013

Dec. 31, 2012

Nov. 30, 2012

Oct. 22, 2012

Jun. 04, 2011

Accrued Interest [Member]

Common stock [Member]

Common stock [Member]

Northstar Biotechnology Group, LLC Promissory Note [Member]

Northstar Biotechnology Group, LLC Promissory Note [Member]

Northstar Biotechnology Group, LLC Promissory Note [Member]

Northstar Biotechnology Group, LLC Promissory Note [Member]

Northstar Biotechnology Group, LLC Promissory Note [Member]

Northstar Biotechnology Group, LLC Promissory Note [Member]

Northstar Biotechnology Group, LLC Promissory Note [Member]

Northstar Biotechnology Group, LLC Promissory Note [Member]

Northstar Biotechnology Group, LLC Promissory Note [Member]

Promissory Note [Member]

Promissory Note [Member]

Officer and Director [Member]

Officer and Director [Member]

Officer and Director [Member]

Officer and Director [Member]

Officer and Director [Member]

Officer and Director [Member]

Officer and Director [Member]

Officer and Director [Member]

Related Party Transactions (Textual)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Advances, related party

$416,198

'

'

$22,750

$313,448

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares issued in conversion of debt

'

7,459,720

'

'

'

'

3,915,662

1,995,614

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amount of debt exchanged for shares

'

1,121,195

'

'

'

'

85,447

'

'

'

'

'

'

'

'

'

'

'

22,750

'

'

'

'

'

'

'

'

'

Common stock issued as payment,shares

'

'

8,771,929

'

'

'

'

'

'

'

'

'

'

'

8,771,929

'

'

'

'

'

'

'

'

'

'

'

'

'

Advances of cash

'

'

100,000

'

'

'

'

'

'

'

'

'

'

'

100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Outstanding principal amount of debt

413,153

'

'

'

'

'

'

'

'

'

'

'

210,000

362,000

'

'

544,267

'

'

'

'

'

1,101,324

'

'

'

'

'

Repayment terms

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'The first of the four monthly payments required under the Note will be due and payable on May, 2012 and all subsequent payments will be due on a monthly basis thereafter commencing on June 1, 2012.

'

'

'

'

'

'

'

'

Warrant issued to purchase shares

'

'

'

'

'

'

'

'

'

'

'

'

5,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Series A convertible preferred stock issued in exchange for payments

'

'

'

'

'

'

'

'

'

'

'

'

'

5,000,000

'

5,000,000

'

5,000,000

'

'

'

'

'

'

'

'

'

'

Common stock issued in exchange for payments

'

'

'

'

'

'

'

'

'

'

'

'

'

10,000,000

'

10,000,000

'

'

'

'

'

'

'

'

'

'

'

'

Value of debt outstanding

'

'

'

'

'

'

'

'

'

'

'

'

'

210,000

'

210,000

'

'

'

'

'

'

'

'

'

'

'

'

Convertible preferred stock issued for penalty settlement

'

'

'

'

'

'

'

'

'

'

'

'

'

15,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value for Preferred Stock

'

'

'

'

'

'

'

'

'

'

'

'

'

274,050

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of revenues to be received as royalty

'

'

'

'

'

'

'

'

'

'

'

8.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Subordinated debt, related party

1,500,000

'

'

'

1,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,500,000

'

1,500,000

'

'

'

Promissory note interest percentage

'

'

'

'

'

8.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5.00%

'

4.75%

'

8.00%

'

'

'

Effective interest rate

'

'

'

5.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5.00%

'

'

'

'

Common stock, voting rights

'

'

'

'

'

'

'

'

'

'

'

'25 votes

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred stock, voting rights

'

'

'

'

'

'

'

'

'

'

'

'20 votes

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Effective interest rate

'

'

'

'

'

'

'

'

'

12.85%

7.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Subordinated notes

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100,000

125,000

140,000

Face value of note

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,278,324

'

'

500,000

'

'

'

'

Debt instrument, Maturity date

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

9-Oct-13

'

'

'

'

'

'

'

Outstanding promissory notes

86,847

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,000

'

'

'

'

'

Common stock issued in settlement of related party notes payable,Shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

15,350,876

'

'

'

'

'

'

Common stock issued in settlement of related party notes payable

$397,750

'

'

'

'

'

'

'

$34,890

'

'

'

'

'

'

'

'

'

'

'

'

$175,000

'

'

'

'

'

'

Derivative_Liabilities_Details

Derivative Liabilities (Details) (USD $)	Aug. 06, 2008	Feb. 04, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Oct. 01, 2012	Oct. 31, 2012	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2012
		Excessive Committed Shares [Member]	Excessive Committed Shares [Member]	Convertible notes [Member]	Convertible notes [Member]	Convertible notes [Member]	Reset warrants [Member]	Reset warrants [Member]	Reset warrants [Member]	Asher notes payable [Member]	Asher notes payable [Member]
					Minimum [Member]	Maximum [Member]
Derivative Liabilities (Textual)	'	'	'	'	'	'	'	'	'	'	'
Increase in common stock, shares, authorized	75,000,000	970,000,000	'	'	'	'	'	'	'	'	'
Fair value of derivative liability	'	$474,954	'	$403,811	'	'	'	'	$148,655	'	'
Fair value of embedded derivatives	'	'	'	256,956	'	'	'	'	'	335,089	76,682
Dividend yield	'	0.00%	'	0.00%	'	'	'	'	0.00%	0.00%	0.00%
Expected volatility	'	156.52%	'	160.41%	'	'	'	'	160.41%	'	222.81%
Risk free interest rate	'	0.38%	'	'	0.07%	0.10%	'	'	3.04%	'	'
Expected term	'	'3 years 6 months	'	'	'3 months 7 days	'7 months 6 days	'	'	'8 years 9 months	'	'9 months 4 days
Loss on change in derivative liabilities	'	'	$84,907	$39,762	'	'	'	'	$74,324	'	'
Common stock purchase warrants issued	'	'	'	'	'	'	'	15,000,000	'	'	'
Exercise price of warrant	'	'	'	'	'	'	0.014	'	'	'	'
Options exercisable period	'	'	'	'	'	'	'10 years	'	'	'	'
Fair value of common stock	'	'	'	$0.01	'	'	'	'	'	'	'

Stockholders_Equity_Details

Stockholders' Equity (Details) (USD $)

1 Months Ended

5 Months Ended

12 Months Ended

173 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

Feb. 22, 2008

Mar. 31, 2003

Dec. 31, 1999

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2009

Dec. 31, 2008

Dec. 31, 2007

Dec. 31, 2006

Dec. 31, 2005

Dec. 31, 2004

Dec. 31, 2003

Dec. 31, 2002

Dec. 31, 2001

Dec. 31, 2000

Dec. 31, 2013

Feb. 04, 2013

Oct. 01, 2012

Aug. 17, 2012

Sep. 19, 2011

Aug. 06, 2008

Sep. 27, 2007

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Jun. 30, 2000

Dec. 31, 2006

Dec. 31, 2005

Dec. 31, 2004

Dec. 31, 2003

Dec. 31, 2002

Dec. 31, 2001

Dec. 31, 2004

Dec. 31, 2003

Dec. 31, 2006

Dec. 31, 2006

Dec. 31, 2010

Dec. 31, 2010

Dec. 31, 2010

Dec. 31, 2010

Dec. 31, 2010

Dec. 31, 2009

Dec. 31, 2010

Dec. 31, 2009

Dec. 31, 2009

Oct. 31, 2009

Dec. 31, 2008

Dec. 31, 2008

Dec. 31, 2013

Dec. 31, 2012

Aug. 17, 2012

Dec. 31, 2011

Votes

Accounts Payable [Member]

Convertible Notes Payable [Member]

Convertible Debt [Member]

Convertible Related Party Notes Payable [Member]

Interest And Penalty [Member]

Chairman of Board [Member]

Chairman of Board [Member]

Chairman of Board [Member]

Chairman of Board [Member]

Chairman of Board [Member]

Chairman of Board [Member]

Chairman of Board [Member]

Vendors [Member]

Vendors [Member]

Maximum [Member]

Minimum [Member]

Common Stock and Warrant Activity One [Member]

Common Stock and Warrant Activity Two [Member]

Common Stock and Warrant Activity Three [Member]

Private Placement [Member]

Private Placement One [Member]

Private Placement One [Member]

Private Placement Two [Member]

Private Placement Three [Member]

Private Placement Four [Member]

Private Placement Four [Member]

Private Placement Five [Member]

Private Placement Five [Member]

Series A Convertible Preferred Stock [Member]

Series A Convertible Preferred Stock [Member]

Series A Convertible Preferred Stock [Member]

Series A Convertible Preferred Stock [Member]

Finder [Member]

Finder [Member]

Votes

Stockholders Equity (Textual)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common stock

'

'

$400,000

$865,000

$509,800

$1,424,800

$2,399,800

$1,859,822

$2,118,505

$3,920,716

$8,124,692

$11,267,554

$4,580,913

$3,182,274

$7,076,198

$6,283,004

$9,608,695

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$234,020

'

'

'

'

'

'

'

'

'

'

'

Issuance of common stock, Shares

'

'

4,324,458

50,029,227

'

22,184,540

'

'

1,230,280

529,432

1,069,699

1,994,556

808,570

561,701

1,092,883

985,668

1,493,575

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,512,890

1,553,885

'

808,210

255,830

2,509,480

'

1,230,280

'

'

'

'

'

Common stock issued under standby equity distribution agreement

'

'

'

31,052,141

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants issued to purchase common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10,000

158,856

1,438,329

453,867

'

26,592

404,105

76,749

752,844

'

369,084

24,325

'

'

'

'

Weighted average exercise price of warrant

'

'

'

'

'

'

$0.15

'

'

'

'

'

'

'

'

'

'

'

'

$0.01

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.23

$0.78

$0.74

$0.68

'

$0.89

$0.20

$0.89

$0.83

'

$2.09

$1.95

'

'

'

'

Gross proceeds from issuance of common stock and warrants

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,800

'

'

852,964

'

'

135,885

188,996

1,740,000

'

2,140,000

'

'

'

'

'

Description of exercisable warrants

'

'

'

'

'

'

'(i) exercisable solely for cash at an exercise price of $0.15 per share, (ii) non-transferable for six months following issuance and (iii) exercisable, in whole or in part, at any time and from time to time during the period commencing on the date that is six months and one day following the date of issuance and ending on the third year anniversary of the date of issuance.

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'(i) exercisable solely for cash at a weighted average exercise price of $0.23 per share, (ii) non-transferable for six months following issuance and (iii) exercisable, in whole or in part, at any time and from time to time during the period commencing on the date that is six months and one day following the date of issuance and ending on the third year anniversary of the date of issuance.

'(i) exercisable solely for cash at a weighted average exercise price of $0.78 per share, (ii) non-transferable for six months following issuance and (iii) exercisable, in whole or in part, at any time and from time to time during the period commencing on the date that is six months and one day following the date of issuance and ending on the third year anniversary of the date of issuance.

'The Warrants are (i) exercisable solely for cash at an weighted average exercise price of $0.74 per share, (ii) non-transferable for six months following issuance and (iii) exercisable, in whole or in part, at any time and from time to time during the period commencing on the date that is six months and one day following the date of issuance and ending on the third year anniversary of the date of issuance.

'(i) exercisable solely for cash at a weighted average exercise price of $0.68 per share, (ii) non-transferable for six months following issuance and (iii) exercisable, in whole or in part, at any time and from time to time during the period commencing on the date that is six months and one day following the date of issuance and ending on the third year anniversary of the date of issuance.

'

'

'(i) exercisable solely for cash at a weighted average exercise price of $0.20 per share, (ii) non-transferable for six months following issuance and (iii) exercisable, in whole or in part, at any time and from time to time during the period commencing on the date that is six months and one day following the date of issuance and ending on the third year anniversary of the date of issuance.

'(i) exercisable solely for cash at a weighted average exercise price of $0.89 per share, (ii) non-transferable for six months following issuance and (iii) exercisable, in whole or in part, at any time and from time to time during the period commencing on the date that is six months and one day following the date of issuance and ending on the third year anniversary of the date of issuance.

'(i) exercisable solely for cash at a weighted average exercise price of $0.83 per share, (ii) non-transferable for six months following issuance and (iii) exercisable, in whole or in part, at any time and from time to time during the period commencing on the date that is six months and one day following the date of issuance and ending on the third year anniversary of the date of issuance.

'

'(i) exercisable solely for cash at a weighted average exercise price of $2.09 per share, (ii) non-transferable for six months following issuance and (iii) exercisable, in whole or in part, at any time and from time to time during the period commencing on the date that is six months and one day following the date of issuance and ending on the third year anniversary of the date of issuance.

'

'

'

'

'

Preferred stock, shares issued

'

'

'

20,000,000

0

'

'

'

'

'

'

'

'

'

'

'

'

20,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

20,000,000

0

'

0

Preferred stock, shares outstanding

'

'

'

20,000,000

0

'

'

'

'

'

'

'

'

'

'

'

'

20,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

0

Preferred stock designated as convertible preferred stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,000,000

'

Number of votes hold by the holder per common share issued in conversion of preferred stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

25

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

20

'

Subscription receivable, Shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

20,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued in exchange for services

'

'

'

85,151

34,600

115,035

360,032

45,900

'

'

16,443

1,210

96,331

823,887

227,503

54,001

52,001

'

'

'

'

'

'

'

'

'

'

'

'

'

16,443

'

'

'

'

'

10,500

24,066

'

'

'

529,520

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued in exchange for services, shares

'

'

'

6,220,263

952,851

1,000,000

529,520

'

'

'

2,903

95,807

'

'

35,137

8,291

7,964

'

'

'

'

'

'

'

'

'

'

'

'

'

2,903

'

'

'

'

'

1,854

4,248

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued in connection with bank guarantor liabilities

'

'

'

'

'

'

2,965,370

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,172,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued in connection with bank guarantor liabilities, Shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,794,430

'

'

'

'

'

'

'

'

'

'

'

'

'

Fees paid to the finder for introducing certain investors to the company

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

17,856

'

'

17,856

'

'

24,325

'

'

'

'

Capital raised through 2008 private placement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,887,032

'

'

'

'

'

'

Sale of common stock, price per share

$5.25

'

'

'

'

'

'

'

'

$7.69

$7.69

$5.67

'

$5.67

$6.47

$6.47

$6.47

'

'

'

'

'

'

'

'

'

'

'

'

'

$5.67

$5.67

$5.67

$5.67

$5.67

$12.94

'

'

$7.69

$5.67

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued in exchange for debt due to travel and other related expenses, shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

95,807

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued in exchange for debt due to travel and other related expenses

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

542,787

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Chairman contributed capital

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

800,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Salary payments for services but not received

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

250,000

'

'

85,830

130,000

250,000

250,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Contributed capital and salary payments converted into common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

15,150

22,946

44,127

81,084

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amount of debt exchanged for shares

'

'

'

'

'

'

1,121,195

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

82,339

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares issued in conversion of debt

'

'

'

'

'

'

7,459,720

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,656,340

2,500,000

57,967,906

34,890,348

9,408,718

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Extinguishment of Debt, Gain (Loss), Net of Tax

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

74,877

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Increase in number of authorized shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

970,000,000

'

'

200,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred stock, shares authorized

'

'

'

20,000,000

5,000,000

'

'

'

'

'

'

'

'

'

'

'

'

20,000,000

20,000,000

'

'

5,000,000

'

5,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred stock, par value

'

'

'

$0.00

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

$0.00

$0.00

'

'

$0.00

'

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock, shares authorized

'

'

'

950,000,000

195,000,000

'

'

'

'

'

'

'

'

'

'

'

'

950,000,000

950,000,000

'

'

195,000,000

50,000,000

50,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock, par value

'

'

'

$0.00

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

$0.00

$0.00

'

'

$0.00

'

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Increase in common stock, shares, authorized

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

75,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Initial public offering of common stock, Shares issue

1,100,000

'

'

'

'

'

'

'

1,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net proceeds from Initial public offering of common stock

1,450,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Underwriter discount

400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance cost of initial public offering of common stock

3,920,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from (payments for) initial public offering of common stock, net

4,240,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,447,829

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Additional cash proceed from initial public offering of common stock

2,790,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Payment of offering expenses

2,790,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of stock options, Shares

'

'

'

'

'

1,982,995

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued upon conversion of notes payable and accrued interest

'

'

'

'

'

1,542,109

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued upon conversion of notes payable and accrued interest, Shares

'

'

'

'

'

27,120,856

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued in settlement of related party advance

'

'

'

'

'

140,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued in settlement of related party advance, Shares

'

'

'

'

'

1,272,730

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrant issued in conversion of debt

'

'

'

'

'

'

3,729,860

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued in connection with the exercise of stock options, issued for accounts payables

'

'

'

'

'

'

831,526

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued upon conversion of notes payable

'

'

'

'

720,214

1,542,109

'

262,224

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued upon conversion of notes payable, Shares

'

'

'

'

51,751,138

27,120,856

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued under "put" agreement

'

'

'

346,914

150,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock shares issued under "put" agreement

'

'

'

'

8,797,859

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued for accrued liabilities

'

'

'

'

14,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued for accrued liabilities, Shares

'

'

'

'

700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued to Chairman of Board as compensation for services, shares

'

'

'

'

'

'

'

'

'

'

'

'

'

67,073

'

81,084

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Recapitalization, description

'

'Two shares of common stock for every one share issued as of that date.

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares owned by Chairman of Board, not participate in recapitalization

'

4,405,541

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued to employees as compensation for services, shares

'

'

'

'

'

'

'

'

'

'

'

'

'

72,980

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued to employees as compensation for services

'

'

'

'

'

'

'

'

'

'

'

'

'

416,383

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Payment not received until January 2001 on number of shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

77,222

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Contribution of Chairman of Board and founding shareholder

'

'

$400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Chairman of Board contributed in exchange for shares of common stock

'

'

4,324,458

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock_option_and_Warrants_Deta

Stock option and Warrants (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Summary of options and activity	'	'	'
Exercised, Shares	'	'	1,982,995
Options outstanding, Shares (Ending Balance)	23,912,943	'	'
Stock Options [Member]	'	'	'
Summary of options and activity	'	'	'
Options outstanding, Shares (Beginning Balance)	7,853,376	4,636,318	'
Granted, Shares	-17,400,000	3,300,000	'
Exercised, Shares	'	'	'
Forfeited/Expired, Shares	-1,340,433	-82,942	'
Options outstanding, Shares (Ending Balance)	23,912,943	7,853,376	4,636,318
Options Exercisable, Shares	6,600,443	3,694,199	'
Available for grant, Shares	32,600,000	'	'
Options outstanding, Weighted - Average Exercise Price (Beginning Balance)	$0.67	$1.20	'
Granted, Weighted - Average Exercise Price	$0.02	$0.04	'
Exercised, Weighted - Average Exercise Price	'	'	'
Forfeited/Expired, Weighted - Average Exercise Price	$1.08	$5.57	'
Options outstanding, Weighted - Average Exercise Price (Ending Balance)	$0.15	$0.67	$1.20
Options exercisable, Weighted - Average Exercise Price	$0.48	'	'
Option granted, Weighted-Average Remaining Contractual Term (in years)	'9 years 10 months 24 days	'	'
Options outstanding, Weighted - Average Remaining Contractual Term (in years)	'9 years	'8 years 2 months 12 days	'8 years 1 month 6 days
Options exercisable, Weighted - Average Remaining Contractual Term (in years)	'8 years	'	'

Stock_option_and_Warrants_Deta1

Stock option and Warrants (Details 1) (Stock Options [Member], USD $)	12 Months Ended
	Dec. 31, 2013
Options outstanding and exercisable for stock-based payment awards	'
Options Outstanding, Shares	23,912,943
Options Outstanding, Weighted-Average Remaining Contractual Term	'9 years
Options Outstanding, Weighted- Average Exercise Price	$0.15
Options Exercisable, Shares	6,600,443
Options Exercisable, Weighted-Average Exercise Price	$0.48
$0.00 - $0.70 [Member]	'
Options outstanding and exercisable for stock-based payment awards	'
Range of Exercise Prices, Minimum	$0
Range of Exercise Prices, Maximum	$0.70
Options Outstanding, Shares	23,290,000
Options Outstanding, Weighted-Average Remaining Contractual Term	'9 years 2 months 12 days
Options Outstanding, Weighted- Average Exercise Price	$0.03
Options Exercisable, Shares	5,977,500
Options Exercisable, Weighted-Average Exercise Price	$0.07
$0.71 - $1.28 [Member]	'
Options outstanding and exercisable for stock-based payment awards	'
Range of Exercise Prices, Minimum	$0.71
Range of Exercise Prices, Maximum	$1.28
Options Outstanding, Shares	162,286
Options Outstanding, Weighted-Average Remaining Contractual Term	'4 years 4 months 24 days
Options Outstanding, Weighted- Average Exercise Price	$0.80
Options Exercisable, Shares	162,286
Options Exercisable, Weighted-Average Exercise Price	$0.80
$5.25 - $5.67 [Member]	'
Options outstanding and exercisable for stock-based payment awards	'
Range of Exercise Prices, Minimum	$5.25
Range of Exercise Prices, Maximum	$5.67
Options Outstanding, Shares	435,945
Options Outstanding, Weighted-Average Remaining Contractual Term	'2 years
Options Outstanding, Weighted- Average Exercise Price	$5.57
Options Exercisable, Shares	435,945
Options Exercisable, Weighted-Average Exercise Price	$5.57
$7.69 [Member]	'
Options outstanding and exercisable for stock-based payment awards	'
Range of Exercise Prices, Minimum	$7.69
Options Outstanding, Shares	24,712
Options Outstanding, Weighted-Average Remaining Contractual Term	'2 years 7 months 6 days
Options Outstanding, Weighted- Average Exercise Price	$7.69
Options Exercisable, Shares	24,712
Options Exercisable, Weighted-Average Exercise Price	$7.69

Stock_option_and_Warrants_Deta2

Stock option and Warrants (Details 2) (USD $)	12 Months Ended		1 Months Ended		12 Months Ended
	Dec. 31, 2011	Dec. 31, 2013	Oct. 02, 2012	Sep. 21, 2012	Dec. 31, 2013	Dec. 31, 2012	Oct. 01, 2012
			Warrant [Member]	Warrant [Member]	Warrant [Member]	Warrant [Member]	Warrant [Member]
Summary of warrants and activity	'	'	'	'	'	'	'
Options outstanding, Shares (Beginning Balance)	'	23,912,943	'	'	74,073,322	32,610,075	'
Options outstanding, Weighted - Average Exercise Price (Beginning Balance)	'	'	'	'	$0.37	$0.86	$0.01
Warrants outstanding, Weighted - Average Remaining Contractual Term (in years)	'	'	'	'	'4 years 6 months	'3 years 9 months 18 days	'
Shares, issued	'	'	15,000,000	5,000,000	50,350,536	42,396,432	'
Warrants, Weighted-Average Exercise Price	'	'	'	'	$0.02	$0.02	'
Warrants, Weighted Average Remaining Contractual Term (in years)	'	'	'	'	'9 years 2 months 12 days	'5 years 9 months 11 days	'
Exercised, Shares	1,982,995	'	'	'	'	'	'
Exercised, Weighted - Average Exercise Price	'	'	'	'	'	$0	'
Forfeited/Expired, Shares	'	'	'	'	-6,345,002	-933,185	'
Forfeited/Expired, Weighted - Average Exercise Price	'	'	'	'	$0.38	$0.76	'
Options outstanding, Shares (Ending Balance)	'	23,912,943	'	'	118,078,856	74,073,322	'
Options outstanding, Weighted - Average Exercise Price (Ending Balance)	'	'	$0.01	$0.02	$0.22	$0.37	$0.01
Warrants Forfeited Weighted Average Remaining Contractual Term	'	'	'	'	'6 years 3 months 18 days	'4 years 6 months	'
Options Exercisable, Shares	'	'	'	'	101,371,743	'	'
Options exercisable, Weighted - Average Exercise Price	'	'	'	'	$0.13	'	'
Warrants exercisable, Weighted - Average Remaining Contractual Term (in years)	'	'	'	'	'5 years 8 months 12 days	'	'

Stock_option_and_Warrants_Deta3

Stock option and Warrants (Details 3) (Warrant [Member], USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Warrants outstanding and exercisable	'	'
Range of Exercise Prices, Maximum	'	$0.03
Range of Exercise Prices, Minimum	'	$0.01
Warrants Outstanding, Shares	118,078,856	'
Warrants Outstanding, Weighted-Average Remaining Contractual Term	'6 years 3 months 18 days	'
Warrants Outstanding, Weighted- Average Exercise Price	$0.22	'
Warrants Exercisable, Shares	101,371,743	'
Warrants Exercisable, Weighted-Average Exercise Price	$0.13	'
0.01 - $0.50 [Member]	'	'
Warrants outstanding and exercisable	'	'
Range of Exercise Prices, Maximum	$0.01	'
Range of Exercise Prices, Minimum	$0.50	'
Warrants Outstanding, Shares	111,829,723	'
Warrants Outstanding, Weighted-Average Remaining Contractual Term	'6 years 3 months 18 days	'
Warrants Outstanding, Weighted- Average Exercise Price	$0.03	'
Warrants Exercisable, Shares	96,667,060	'
Warrants Exercisable, Weighted-Average Exercise Price	$0.03	'
0.52 - $0.68 [Member]	'	'
Warrants outstanding and exercisable	'	'
Range of Exercise Prices, Maximum	$0.52	'
Range of Exercise Prices, Minimum	$0.68	'
Warrants Outstanding, Shares	2,699,675	'
Warrants Outstanding, Weighted-Average Remaining Contractual Term	'5 years 3 months 18 days	'
Warrants Outstanding, Weighted- Average Exercise Price	$0.58	'
Warrants Exercisable, Shares	2,699,675	'
Warrants Exercisable, Weighted-Average Exercise Price	$0.58	'
0.70 - $1.62 [Member]	'	'
Warrants outstanding and exercisable	'	'
Range of Exercise Prices, Maximum	$0.70	'
Range of Exercise Prices, Minimum	$1.62	'
Warrants Outstanding, Shares	848,176	'
Warrants Outstanding, Weighted-Average Remaining Contractual Term	'6 years	'
Warrants Outstanding, Weighted- Average Exercise Price	$0.71	'
Warrants Exercisable, Shares	848,176	'
Warrants Exercisable, Weighted-Average Exercise Price	$0.71	'
5.67 - $7.69 [Member]	'	'
Warrants outstanding and exercisable	'	'
Range of Exercise Prices, Maximum	$5.67	'
Range of Exercise Prices, Minimum	$7.69	'
Warrants Outstanding, Shares	2,701,282	'
Warrants Outstanding, Weighted-Average Remaining Contractual Term	'8 years 10 months 24 days	'
Warrants Outstanding, Weighted- Average Exercise Price	$7.55	'
Warrants Exercisable, Shares	1,156,832	'
Warrants Exercisable, Weighted-Average Exercise Price	$7.35	'

Stock_option_and_Warrants_Deta4

Stock option and Warrants (Details Textual) (USD $)

12 Months Ended

173 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Aug. 06, 2012

Jan. 16, 2012

Oct. 02, 2012

Sep. 21, 2012

Dec. 31, 2013

Dec. 31, 2012

Oct. 01, 2012

Dec. 31, 2011

August 5, 2013 [Member]

August 1, 2013 [Member]

September 1, 2013 [Member]

Stock Options [Member]

Stock Options [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Stock Options and Warrants (Textual)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted average exercise price

'

'

'

'

'

'

$0.03

$0.10

$0.01

$0.02

$0.22

$0.37

$0.01

$0.86

Shares, issued

'

'

'

4,890,000

15,000,000

2,400,000

'

'

15,000,000

5,000,000

50,350,536

42,396,432

'

'

Exercised, Weighted - Average Exercise Price

'

'

'

$0.02

$0.02

$0.02

'

'

'

'

'

$0

'

'

Gross change in fair value, determined using Black Scholes option pricing model

'

'

'

$1,630

$245,749

$37,823

'

'

'

'

'

'

'

'

Range of Exercise Prices, Minimum

'

'

'

$0.03

'

'

'

'

'

'

'

$0.01

'

'

Range of Exercise Prices, Maximum

'

'

'

$0.21

'

'

'

'

'

'

'

$0.03

'

'

Granted, Shares

'

'

'

'

'

'

2,800,000

500,000

'

'

'

'

'

'

Dividend rate

'

'

'

'

0.00%

0.00%

0.00%

0.00%

0.00%

0.00%

'

'

'

'

Volatility rate

'

'

'

'

153.27%

150.98%

164.91%

164.79%

155.41%

163.45%

'

'

'

'

Risk free interest rate

'

'

'

'

2.74%

2.78%

1.59%

1.89%

1.64%

1.78%

'

'

'

'

Options vesting period

'

'

'

'

'

'

'4 years

'4 years

'

'

'

'

'

'

Fair value of the option vested

125,515

76,674

'

'

'

'

'

'

311,190

119,023

'

'

'

'

Warrants expiration period

'

'

'

'

'

'

'

'

'10 years

'10 years

'

'3 years

'

'

Options exercisable period

'

'

'

'

'4 years

'

'

'

'

'

'

'6 months

'

'

Interest Expense

$1,437,883

$1,619,653

$15,951,457

'

$25,599

'

'

'

'

'

'

'

'

'

Commiments_and_Contingencies_D

Commiments and Contingencies (Details) (USD $)	Dec. 31, 2013
Schedule of future minimum lease obligations under non cancelable operating lease agreements	'
2013	$48,195
Total	$48,195

Commiments_and_Contingencies_D1

Commiments and Contingencies (Details 1) (USD $)	Dec. 31, 2013
Future minimum obligations under the agreement	'
2014	$210,000
2015	210,000
Total	$420,000

Commiments_and_Contingencies_D2

Commiments and Contingencies (Details Textual) (USD $)	1 Months Ended			12 Months Ended				173 Months Ended	1 Months Ended
	Jul. 31, 2013	Feb. 28, 2010	Jun. 30, 2000	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2013	Nov. 20, 2013	Dec. 31, 2013
				Employees					Consulting Agreements [Member]	Consulting Agreements [Member]
Commitments and Contingencies (Textual)	'	'	'	'	'	'	'	'	'	'
Lease term, Description	'In July 2013, the Company amended its facility lease to extend the term of the lease until July 31, 2014.	'In February 2010, the Company amended its facility lease to extend the term of the lease until January 2013.	'	'	'	'	'	'	'	'
Rent expense	'	'	'	$123,216	$89,507	'	'	$2,102,062	'	'
Patent expiration period	'	'	'2015	'	'	'	'	'	'	'
Payment made to acquire license	'	'	55,000	'	'	'	'	'	'	'
Annual license fee payable	'	'	10,000	'	'	'	'	'	'	'
Royalties payable	'	'	'2% to 4% of net sales of products that are covered by the patents.	'	'	'	'	'	'	'
Minimum royalty threshold	'	'	'	'	200,000	200,000	200,000	'	'	'
Liability under license agreement	'	'	'	2,122,130	1,825,675	'	'	2,122,130	'	32,424
License expenses incurred	'	'	'	210,000	210,000	'	'	2,122,130	'	'
Accrued interest for past due commitment under license agreement	'	'	'	'At 2% over the prime rate.	'	'	'	'	'	'
Accrued expenses	'	'	'	2,122,130	'	'	'	2,122,130	'	'
Number of persons with continuing right to rescission	'	'	'	2	'	'	'	'	'	'
Repurchase consideration for unexercised options	'	'	'	'77% of the option exercise price multiplied by the number of option shares, plus interest at the rate of 7% from the date the options were granted.	'	'	'	'	'	'
Total rescission liability	'	'	'	371,000	'	'	'	371,000	'	'
Contingent Liability	'	'	'	$0	$0	'	'	$0	'	'
Fess received by Cassel Salpeter & Co	'	'	'	'	'	'	'	'	'CSC will receive a one-time $25,000 fee, $5,000 monthly fees.	'
Common stock purchase warrants	'	'	'	'	'	'	'	'	5,207,630	'
Warrants exercisable	'	'	'	'	'	'	'	'	$0.01	'
Warrant term	'	'	'	'	'	'	'	'	'10 years	'

Income_Taxes_Details

Income Taxes (Details) (USD $)	12 Months Ended		173 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Summary of federal statutory corporate tax rate and actual income tax expense	'	'	'
Income taxes using U.S. federal statutory rate	($1,068,708)	($1,365,599)	'
State income taxes, net of federal benefit	-108,788	-80,708	'
Stock Option Expirations	78,864	326,995	'
Net Operating Loss adjustments	-20,008	196,416	'
Nontaxable Gain on Derivative Instrument	-9,921	-40,730	'
Change in Valuation Allowance	1,127,875	974,536	'
Other	686	-10,910	'
Income taxes (benefit)	'	'	'

Income_Taxes_Details_1

Income Taxes (Details 1) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Deferred tax assets:	'	'
Stock Based Compensation	$4,465,854	$4,505,907
Net Operating Losses	35,429,429	34,266,157
Other	125,317	120,661
Total deferred tax assets	40,020,600	38,892,725
Deferred tax liabilities:	'	'
Total deferred tax liabilities	'	'
Valuation allowance	40,020,600	38,892,725
Net deferred tax assets	'	'

Income_Taxes_Details_Textual

Income Taxes (Details Textual) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
		U.S. Federal [Member]	U.S. Federal [Member]	State Jurisdiction [Member]	State Jurisdiction [Member]
Income Taxes (Textual)	'	'	'	'	'
Operating loss carryforwards, net	'	$94.20	$91.10	$94.20	$91.10
Operating loss carryforwards, expiration dates	'Expire at various dates from 2019 through 2033.	'	'	'	'
Annual limit of corporation to reduce its tax liability	'An annual limit on the ability of a corporation that undergoes a greater than 50% ownership change to use its net operating loss carry forwards to reduce its tax liability.	'	'	'	'
Operating loss carryforwards, expiration dates for state income tax	'At various dates from 2019 through 2033.	'	'	'	'
Description of equity method ownership change	'If in the future the Company issues common stock or additional equity instruments convertible in common shares which result in an ownership change exceeding the 50% limitation threshold imposed by section 382 of the Code, the Company's net operating loss carry-forwards may be significantly limited as to the amount of use in a particular years.	'	'	'	'
Income tax examination, description	'The periods from December 31, 2006 to December 31, 2013 remain open to examination by the U.S. Internal Revenue Service, and state tax authorities.	'	'	'	'

Fair_Value_Measurement_Details

Fair Value Measurement (Details) (USD $)	12 Months Ended		173 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Summary of changes in fair value of the Company's Level 3 financial liabilities	'	'	'
Beginning Balance	$611,227	'	'
Total (gains) losses	'	'	'
Initial fair value of derivative relating to exceeding authorized common shares	'	-427,663,000	'
Balance	403,811	611,227	403,811
Net Gain for the period included in earnings relating to the liabilities held at December 31, 2013	29,179	119,795	123,948
Excess Share Derivative [Member]	'	'	'
Summary of changes in fair value of the Company's Level 3 financial liabilities	'	'	'
Beginning Balance	390,048	'	'
Total (gains) losses	'	'	'
Initial fair value of debt derivative at note issuance	'	'	'
Initial fair value of derivative relating to reset warrants	'	'	'
Initial fair value of derivative relating to exceeding authorized common shares	'	427,663	'
Mark-to-market	84,906	-37,615	'
Transfers out of Level 3 upon conversion and settlement of notes	'	'	'
Balance	'	390,048	'
Transfers out of Level 3 upon increase in authorized shares	-474,954	'	'
Transfers out of Level 3 upon conversion of notes payable	'	'	'
Warrant [Member]	'	'	'
Summary of changes in fair value of the Company's Level 3 financial liabilities	'	'	'
Beginning Balance	221,179	'	'
Total (gains) losses	'	'	'
Initial fair value of debt derivative at note issuance	'	'	'
Initial fair value of derivative relating to reset warrants	'	311,190	'
Initial fair value of derivative relating to exceeding authorized common shares	'	'	'
Mark-to-market	-74,324	-90,011	'
Transfers out of Level 3 upon conversion and settlement of notes	'	'	'
Balance	146,855	221,179	146,855
Transfers out of Level 3 upon conversion of notes payable	'	'	'
Debt Derivative [Member]	'	'	'
Summary of changes in fair value of the Company's Level 3 financial liabilities	'	'	'
Beginning Balance	'	'	'
Total (gains) losses	'	'	'
Initial fair value of debt derivative at note issuance	673,219	76,862	'
Initial fair value of derivative relating to reset warrants	'	'	'
Initial fair value of derivative relating to exceeding authorized common shares	'	'	'
Mark-to-market	-39,761	7,651	'
Transfers out of Level 3 upon conversion and settlement of notes	'	-84,513	'
Balance	256,956	'	256,956
Transfers out of Level 3 upon conversion of notes payable	($376,502)	'	'

Fair_Value_Measurement_Details1

Fair Value Measurement (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Fair Value Measurement (Textual)	'	'	'
Derivative instruments that were designated as hedges	$0	$0	'
Derivative liability	$403,811	$611,227	'
Percentage of stock price decrease	50.00%	'	'
Change in pricing inputs	'A 10 percent change in pricing inputs and changes in volatilities and correlation factors would result in less than a $60,318 change in our Level 3 fair value.	'	'

Subsequent_Events_Details

Subsequent Events (Details) (USD $)

5 Months Ended

12 Months Ended

173 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

Dec. 31, 1999

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2009

Dec. 31, 2008

Dec. 31, 2007

Dec. 31, 2006

Dec. 31, 2005

Dec. 31, 2004

Dec. 31, 2003

Dec. 31, 2002

Dec. 31, 2001

Dec. 31, 2000

Dec. 31, 2013

Feb. 23, 2014

Feb. 28, 2014

Jan. 31, 2014

Feb. 28, 2014

Feb. 28, 2014

Feb. 10, 2014

Jan. 14, 2014

Jan. 23, 2013

Feb. 19, 2014

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Maximum [Member]

Minimum [Member]

Asher Enterprises Inc [Member]

Asher Enterprises Inc [Member]

Asher Enterprises Inc [Member]

Daniel James Management Inc [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Events (Textual)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued in exchange for services, shares

'

6,220,263

952,851

1,000,000

529,520

'

'

'

2,903

95,807

'

'

35,137

8,291

7,964

'

'

'

1,977,155

'

'

'

'

'

'

Common stock issued in exchange for services

'

$85,151

$34,600

$115,035

$360,032

$45,900

'

'

$16,443

$1,210

$96,331

$823,887

$227,503

$54,001

$52,001

'

'

'

$12,000

'

'

'

'

'

'

Amount of debt exchanged for shares

'

'

'

'

1,121,195

'

'

'

'

'

'

'

'

'

'

'

300,000

10,000

15,000

'

'

'

'

'

'

Common shares issued in conversion of debt

'

'

'

'

7,459,720

'

'

'

'

'

'

'

'

'

'

'

'

1,746,032

2,941,176

'

'

'

'

'

'

conversion price of notes payable

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.02

'

'

'

'

'

'

'

Issuance of common stock, Shares

4,324,458

50,029,227

'

22,184,540

'

'

1,230,280

529,432

1,069,699

1,994,556

808,570

561,701

1,092,883

985,668

1,493,575

'

'

25,114,500

'

'

'

'

'

'

'

Exercise price of warrant

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.0214

0.011

'

'

'

'

Proceeds from issuance of common stock, net

'

1,426,914

584,800

'

'

'

'

'

'

'

'

'

'

'

'

65,308,689

'

331,500

'

'

'

'

'

'

'

Common stock issued in settlement of subscriptions received, shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,925,442

'

'

'

'

'

'

'

Common stock issued in settlement of subscriptions received

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

55,000

'

'

'

'

'

'

'

Options granted to purchase common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

15,000,000

'

'

'

'

'

'

'

'

Options vesting period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'4 years

'

'

'

'

'

'

'

'

Options exercisable period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'10 years

'5 years

'

'

'

'

'

'

'

Additional Options Granted

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

400,000

'

'

'

'

'

'

'

'

Excercise price of options

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.02

'

'

'

'

'

'

'

'

Number of warrants granted

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

25,114,500

'

'

'

'

'

'

'

Convertible debt, principle amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$32,500

'

$42,500

$35,000

Promissory note interest percentage

'

'

'

8.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8.00%

'

8.00%

8.00%

Debt instrument, Maturity date

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

12-Nov-14

16-Oct-14

'

18-Feb-15

Note conversion, description

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'The Note is convertible into common stock, at Asher's option, at a 45% discount to the average of the three lowest closing bid prices of the common stock during the 10 trading day period prior to conversion. In the event the Company prepays the Note in full, the Company is required to pay off all principal, interest and any other amounts owing multiplied by (i) 140% if prepaid during the period commencing on the closing date through 179 days thereafter. After the expiration of 180 days following the date of the Note, the Company has no right of prepayment.

'The Note is convertible into common stock, at Asher's option, at a 45% discount to the average of the three lowest closing bid prices of the common stock during the 10 trading day period prior to conversion. In the event the Company prepays the Note in full, the Company is required to pay off all principal, interest and any other amounts owing multiplied by (i) 140% if prepaid during the period commencing on the closing date through 179 days thereafter. After the expiration of 180 days following the date of the Note, the Company has no right of prepayment.

'

'The Note is convertible into common stock, at Asher's option, at a 47% discount to the lowest daily closing bid price of the common stock during the 10 trading day period prior to conversion. In the event the Company prepays the Note in full, the Company is required to pay off all principal at 150%, interest and any other amounts.